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ABSTRACT 
A series of new hybrid 2-(diethoxyphosphoryl)-N-(benzylidene)propan-2-amine oxide derivatives with 
different aromatic substitution (PPNs) were synthesized. These molecules were evaluated for their EPR 
spin trapping potential and NO donation properties in vitro, their cytotoxicity and on precontracted rat 
aortic rings. A subfamily of the new PPNs featured an antioxidant moiety occurring in natural phenolic 
acids. From the experimental screening of these hydroxyphenyl- and methoxyphenyl-substituted PPNs, 
biocompatible nitrones 4d, 4g−i deriving from caffeic, gallic, ferulic and sinapic acids, which combined 
improved EPR probing of ROS formation, vasorelaxant action and antioxidant potency, might be 
potential drug candidate alternatives to PBN and its analogues. 
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1. Introduction 
Oxidative stress usually refers to an imbalance between cellular formation of reactive oxygen species 
(ROS), including free radicals (e.g., superoxide (O2.
-
) and hydroxyl radicals (HO.)) and non-radical 
oxidants (e.g., hydrogen peroxide (H2O2) or peroxynitrite), and efficacy of cell antioxidant defense 
machinery (e.g., superoxide dismutase, catalase, ascorbate) [1,2]. Many triggers of ROS formation have 
been identified, such as activation of endogenous enzymes (e.g., xanthine or NADPH oxidases) or 
exposure to UV light, ionizing radiations, toxins, cigarette smoke or environmental pollutants [1]. The 
concept of oxidative stress was recently re-defined as a disruption of redox signaling and control, a new 
perception that stimulated many investigations toward the role of cellular nucleophiles such as 
glutathione, or the identification of key enzymes perturbations [2-4]. Although it was now established 
that low levels of certain ROS can enhance cell defense capacity [2,5], there is a tremendous body of 
evidence from animal studies and clinical trials that a massive release of ROS contribute to the initiation 
and progression of a variety of chronic diseases such as inflammation, cancer, cardiovascular and 
neurodegenerative disorders, or acute iron overload-induced poisoning [1,6]. 
In this context, the discovery of antioxidant molecules to regulate oxidative stress-related diseases has 
become a challenging area of pharmaceutical chemistry. In most investigations, the privileged targets are 
natural or synthetic substances having improved ability to (i) interrupt free radical-mediated chains of 
cell lipid peroxidation by scavenging free radicals or inactivating metal ions catalysts such as Fe
2+
 or (ii) 
retard or prevent new free radical chains to form, e.g., by decreasing local oxygen concentration [7-10]. 
Phenolic compounds Ar−OH (many classes of them being abundant in plants) are the most effective 
antioxidants since they can meet some essential conditions of good chain-breaking antioxidants, i.e., (i) 
they are effective H donors due to relatively low O−H bond dissociation energies, (ii) their interaction 
with propagating radicals, e.g., peroxyl radicals ROO., forms unreactive, resonance-stabilized phenoxyl 
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radicals ArO., thus stopping peroxidation chains, (iii) they have ionization potentials high enough to 
prevent the formation of O2.
-
 from molecular oxygen by electron transfer, and (iv) they generally show 
suitable chemical properties such as iron chelation or increased lipophilicity to reach cell membranes 
[7,8]. In addition some of them were shown to inhibit initiating enzymes such as xanthine oxidase or 
directly scavenge the primarily formed O2.
- 
[1,7,8]. Owing to these unique antioxidant properties, 
hundreds of natural and synthetic phenolics have been isolated or produced in the last 50 years and 
tested as inhibitors of oxidative stress and a further step to increase their biological efficacy would be to 
design multipotent hybrid compounds having additional sites for free radical scavenging. 
Nitrones such as α-phenyl-N-tert-butyl nitrone (PBN; Figure 1A) have been used extensively to 
characterize non-persistent free radicals using the EPR / spin trapping technique [11]. Three decades 
ago, Novelli and co-workers [12] opened the way to the therapeutic use of nitrones by reporting that i.p. 
administration of PBN efficiently decreased traumatic shock in rats. From then on, PBN and a growing 
number of its congeners have demonstrated biological activity in a variety of free radical-related 
disorders, including ischemia/reperfusion, brain or renal injury, retinal and neuronal damage [13]. 
Although the therapeutic efficacy of PBN-type nitrones (PBNs) in systems exposed to ROS may be 
consistently relevant to free radical scavenging, other mechanisms have been highlighted, such as iNOS 
and COX-2 gene induction suppression [14], modulation of phase II enzymes and caspase-3 activities 
[15]
 
or activation of Ras-ERK pathway [16]. Moreover, in aqueous media, PBN [17] and other nitrones 
were shown to release nitric oxide (NO), a free radical implicated in both physiological and stress-
related signaling. Indeed, this chemical property of PBN is increasingly invoked to explain some of its 
pharmacological actions [16,18]. Among the increasing number of available PBNs designed for a 
therapeutic purpose, most were elaborated on the basis of cell targeting, bioavailability or increased 
membrane crossing [13,19,20], and if a few were built around a phenolic-based antioxidant scaffold [21-
24] (Figure 1A), no further structural modification of the non aromatic side of the nitrone function was 
done to improve the EPR detection of spin adducts. 
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In the search for biocompatible probes of oxidative stress acting both as antioxidants and EPR 
analytical tools, we describe herein the synthesis and biological evaluation of a new class of hybrid, 
natural product-inspired PBN derivatives bearing a diethoxyphosphoryl substituent on the N-alkyl arm. 
Because of the recognized antioxidant properties of food phenolics from diet, such as gallic, caffeic, 
ferulic and sinapic acids [25], and their implication in the prevention of many oxidative stress-related 
pathologies [26], their aromatic frameworks, which only contained hydroxy and methoxy substituents, 
were selected in the design of eight novel antioxidant-based nitrones (termed as PPNs; Figure 1B). The 
choice of incorporating a P(O)(OEt)2 group was motivated both by its high biocompatibility [27,28] and 
the fact that O2.
-
 and HO. spin adducts of the parent 2-(diethoxyphosphoryl)-N-(benzylidene)propan-2-
amine oxide (PPN) showed increased stabilities vs PBN in buffers [29]. 
In this paper, we first screened the new antioxidant-based PPNs using EPR spin trapping, spontaneous 
NO-releasing, lipophilicity, cytotoxicity and antioxidant endpoints, in comparison with relevant 
standards, PBN, PPN, and nine additional non phenolic PPNs, with seven of them being newly 
described (Figure 1B). In a second part of the study, PPNs with the best overall antioxidant and/or NO 
donation properties were tested in a model a free radical-challenged rat aortic rings both for their EPR 
detector properties and protective effect against vasorelaxant function impairment and protein 
carbonylation. 
 
Results and Discussion 
Chemistry and Crystallographic Analysis. The synthesis of the fifteen new PPNs was carried out 
using methodology developed for the synthesis of the unsubstituted PPN [30], with a few modifications 
for the first two steps (Scheme 1). Thus, the yield of β-phosphorylated amine 1 was increased up to 75% 
by treating by 20% NaOH the crude product dissolved in chloroform and further oxidation of 1 by 2 eq. 
KMnO4/MgSO4 gave the corresponding nitrophosphonate 2 in 70% yield. The key hydroxylamine 3 was 
then obtained by Zn/NH4Cl reduction of 2 and PPNs 4a−r (Figure 1B) were obtained in moderate to 
good yields by condensing the corresponding substituted benzaldehyde on 3 in THF or DCE at 100 °C. 
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Scheme 1. General Synthesis of PPNs 4a−ra 
 
a
Reagents and conditions: (a) HP(O)(OEt)2, NH3, acetone, 5 °C, 2 h, 75%; (b) 2 eq KMnO4, 2 eq. 
MgSO4, acetone:water (7.5:1), 50−55 °C, 1 day, 70%; (c) Zn, NH4Cl, water, -10 °C, then 2 h, room 
temp., then 50-55 °C, 1 h, 53%; (d) ArCHO, THF or DCE, 100 °C, 4 h, 32−87%. 
 
Nitrones 4b, 4f, 4k and 4q, which were obtained as single crystals, were analyzed by X-ray 
diffraction. Selected crystal parameters are given in Table 1 and characteristic ORTEP drawings [31] 
with 50% probability displacement thermal ellipsoids are depicted in Figure 2 for 4b and 4q. The four 
PPNs crystallized as Z-isomers, i.e., the aromatic ring and the N(
+
)−O- bond are in syn position, a 
geometry also found for 4-OH-PPN 4c [32]. Two types of intramolecular H-bonds toward the negatively 
charged oxygen of the nitrone function establish in 4b, 4k and 4q (Figure 2 and Figure S1A in 
Supporting Information), i.e., one linking one ortho-H atom of the ring (in 4b and 4k), and the other one 
linking one methylene hydrogen of the P(O)(OEt)2 group (in 4k and 4q). Comparison of 
crystallographic data of the new PPNs vs 4c [32] also reveals even shorter C=N bond distances in 4f and 
4q (Table 1). In the case of compound 4f (which crystallises as [4f−4f] and [4f−4f’] dimers with 
intermolecular − and CH− stacking interactions), a third type of intramolecular H-bond exist 
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between the oxygen of the nitrone function and the hydroxyl group in ortho-position (Supporting 
Information, Figure S1B). As expected from the weak steric effect of meta substitution of the phenyl 
ring, the C=N bond and the aromatic ring in 4b are nearly coplanar, allowing C(10)−P(11) bond to 
preferentially occupy a position below the C(1)−N(8)−O(9) plane, with a O(9)−N(8)−C(10)−P(11) 
dihedral angle close to 90° (Figure 2A; see also Figure S1A for 4k). Conversely, due to the high 
bulkiness of the 2,6-Me-Phenyl, a minimum steric interaction in 4q is obtained when both the 
P(O)(OEt)2 and the aromatic groups hinder almost equally the two faces of the C=N spin trapping site 
(Figure 2B). Consistently, the high steric strain in 4q also resulted in the longest C(1)−C(2) bond (Table 
1). These steric-induced differences in both accessibility at C(1) and C(1)−C(2) bond lengths should 
affect the spin trapping and NO releasing properties of the PPNs, respectively (see below), although 
importance of solvation should be considered. 
 
EPR Spin Trapping Studies. Note: to simplify, acronyms indicating aromatic substitution as 
indicated in Figure 1B were chosen to designate each of the PPNs and the related R. radical spin adducts 
were termed as PPNs-R. 
The spin trapping properties of the new PPNs were first investigated in vitro against a series of 
carbon-, nitrogen- and sulfur-centered radicals in water or phosphate buffer at near-neutral (pH 7.4; 
nPB) or acidic (pH ~4; acPB) pH. In general, typical EPR spectra of nitroxides resulting from radical 
addition to PPNs retain the basic feature of PBNs spin adducts, i.e., a triplet of doublets (nitrogen (aN) 
and β-hydrogen (aH) couplings), with extra splitting by a large 
31P β-coupling (aP). For the parent PPN 
and its hydroxy- and methoxy-substituted derivatives 4a−i, the hyperfine splitting constants (hfscs) 
extracted from computer simulation of the experimental EPR signals, together with some characteristic 
g-values of spin adducts, are listed in Table 2. To assess the importance of steric and electronic effects 
of aromatic substituents on hfscs, the trapping experiments were also carried out on PPNs 4j−p 
substituted with electron-withdrawing groups or one ortho group (Table 3). Hence, for a given PPNs-R 
adduct, ortho/para substituents would increase spin density on nitrogen (which determines the 
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magnitude of aN) if they are electron-donating (such as hydroxy or methoxy groups), or conversely 
decrease aN if they are electron-withdrawing (such as nitro, acid or ester groups), while meta-
substituents woud have no or little effect on aN. This tendency was actually observed among PPNs-R 
adducts but, compared to the corresponding adducts with PPN itself, aN values were affected to a modest 
extent, not exceeding +0.03 and −0.05 mT for electron-donating (Table 2) or withdrawing (Table 3) 
groups, respectively. 
Even for nitrones scarcely soluble in aqueous media, rather intense and long-lasting signals were 
detected when the sulfur trioxide anion radical (SO3.
-
) or carbon-centered radicals were trapped in nPB, 
an improved stability reported for the few previously tested PPNs [29,30,32]. As anticipated from its X-
ray structure revealing high steric effect around the nitrone function (Figure 2B), most spin trapping 
experiments on 2,6-Me-PPN 4q were unsuccessful, with the notable exception of CO2.
-
 which added to 
the nitrone to yield a weak composite signal containing the expected 2,6-Me-PPN-CO2H adduct, with aN 
= 1.467; aH = 0.702; aP = 4.112 mT, and ~50% of a decomposition triplet (aN = 1.628 mT). 
Regardless of the trapped species, the largest aH values were found among the other ortho-substituted 
PPNs 4a,f, j,p, indicating that steric hindrance increases spin density on the β-hydrogen. The same trend 
was reported for hindered adducts of nitrones carrying two ortho-substituents such as 2,4,6-OMe-PBN 
[33] and 2,4,6-OMe-PPN [30]. For a given PPNs, both aH and aP augmented with decreasing size of the 
trapped alkyl radical, yielding significant differences in the spectrum total width (STW) [29]. Thus, 
going from methyl radical to the bulkier α-hydroxyethyl radical led to a STW decrease of ca. 0.65 mT 
for antioxidant-based PPNs (4d, 4g−i), a value reaching 0.80 and 1.18 mT for ortho-substituted 4a and 
4p, respectively. A STW difference of 0.75 mT has been reported earlier between the CO2.
-
 spin adducts 
of 3- and 4-pyridyl substituted PPNs [30] which cannot originate from a change in steric hindrance. 
Here, PPNs-CO2H adducts of NO2- and OH-substituted nitrones showed even larger STW differences, 
e.g., it was +0.93 mT between 4-OH-PPN 4c and 2-OH-PPN 4a (Table 2) and +1.13 mT between 4-
NO2-PPN 4l and 2-NO2-PPN 4j (Table 3) and both cases it was spin density at phosphorus which 
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significantly decreased with increasing steric bulk of the substituent. Regarding PPNs-SO3H adducts, 
which were reported here for the first time, we found no straightforward explanation to interpret the 
interplay between nitrone structure and (aH, aP) variations. Again, strong STW differences were found 
among these spin adducts, e.g., it was of 6.85 mT for 2-CF3-PPN-SO3H and 7.33 mT for 4-OH-3,5-
OMe-PPN-SO3H with aP values as different as 3.990 and 4.479 mT, respectively (Figure 3A,B). 
Contrary to the trapping experiments described above, only a limited number of PPNs gave detectable 
PPNs-N3 or PPNs-H adducts in aqueous media, the latter being formed by NaBH4 reduction of the 
nitrone (Table 3). Expectedly, azidyl radical (N3.) spin adducts exhibited an additional long-range 
nitrogen coupling such as in PPN-N3 (aN = 1.397; aH = 0.221; aP = 4.475 and aNβ = 0.181 mT) while in 
PPNs-H spectral simulations were in agreement with two equivalent β-hydrogen hfscs (for PPN-H: aN = 
1.534; aH = 1.061 (2H); aP = 4.851 mT). 
We next examined if the new PPNs could form EPR detectable spin adducts with oxygen-centered 
radicals in aqueous environment and for this purpose we used PPN, 4-NO2-PPN 4l and 4-Cl-PPN 4r as 
benchmarks since their O2.
-
, HO. and CH3O. spin adducts were characterized previously [29,30,34]. To 
generate O2.
-
 / HOO. in aqueous milieu, we used alternatively a xanthine/xanthine oxidase system in 
nPB or UV-photolysis of 30% H2O2 in water and, in our hands, PPN was the only nitrone that yielded 
moderately stable PPN-OOH with both systems, with hfscs from the enzymatic (photolytic) generator 
of: aN = 1.359 (1.366), aH = 0.226 (0.235), and aP = 4.129 (4.173) mT. Photolytically generated HOO. 
radicals gave rather strong PPNs-OOH EPR signals with all non-phenolic PPNs (Figure 3C), whose 
hfscs are in agreement with those of PPN-OOH [30], and which again showed a dramatic increase in aH 
value with steric hindrance, as in 4j and 4p (Table 3). However, such addition of HOO. in aqueous 
medium failed to yield detectable levels of PPNs-OOH signals in the particular case of hydroxy- and 
methoxy-substituted PPNs 4a−i. However, using nucleophilic addition of H2O2 in a polar aprotic solvent 
such as pyridine as a means to produce PPNs-OOH, the expected EPR signals having g-values ~2.0060 
were observed for most of the tested PPNs (Tables 2 and 3), with the notable exception of 4-OH-3,5-
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OMe-PPN 4i which afforded a transient decomposition spectrum, whose simulated couplings are 
compatible with the corresponding β-phosphorylated benzoyl nitroxide PPNsOX-1 (i.e., 4-OH-3,5-
OMe-PPNsOX) where, due its Ar-C(O)−N(O.) structure, spin density is delocalized through the 
aromatic ring (hfscs: aN = 0.500; aP = 0.932; aortho-H (2H) = 0.371; aH-OMe (6H) = 0.177; aH-para-OH = 0.090 
mT; g = 2.0062; Figure S2 in Supporting Information). 
In another hand, when HO. radicals were generated by a Fenton reaction in acPB only PPN and a few 
nitrones among compounds 4j−r, but none of the antioxidant-based PPNs 4a−i, yielded PPNs-OH 
adducts. EPR signals lasted only a few minutes, showing g-values of ~2.0057 and hfscs summarized in 
Table 3 in agreement with literature data for the HO. adducts of 4-Cl-PPN 4r and 4-NO2-PPN 4l 
[29,30]. Thus, we obtained for PPN-OH at pH 4.5: aN = 1.426; aH = 0.248; aP = 4.313 mT; g = 2.00561. 
From our observations and similar reported earlier [29,30], the presence of a P(O)(OEt)2 group in the 
PPNs structure did result in an increase of PPNs-OH stability vs PBNs-OH (e.g., half-life of PBN-OH in 
buffer is only 90 s at pH 6 [35]), but this effect has not yet been quantified to our knowledge. 
In marked contrast with HO., long-lasting methoxy radical adducts PPNs-OCH3 were easily detected 
in DMSO/methanol (75:25) solution with most of the tested PPNs using the reaction of lead tetraacetate 
with the alcohol followed by aerial oxidation as the free radical generator (Figure 3D). One must notice 
that in this system antioxidant-based nitrones 4g and 4i yielded the benzoyl nitroxides PPNsOX-2,3, 
respectively instead of the expected adduct (Tables 2 and 3). Despite they both arise from nitrone 4i the 
observed strong difference in EPR spectrum shapes and hfscs strongly suggest PPNsOX1 and PPNsOX3 
are different species. Until now only a few other PPNs-OCH3 adducts have been described in the 
literature [32,34]. 
In the spin trapping respect, the lack of detection of O2.
-
/ HO. adducts of antioxidant-constructed 
nitrones 4a−i, which like other PPNs yet contain a stabilizing P(O)(OEt)2 group, may be a consequence 
of preferential attack on the phenolic sites rather than on the nitrone function. Hence, the reaction of 
bulky RO. radicals on BHT-PBN (Figure 1) in benzene selectively yielded the persistent, di-ortho-tert-
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butyl protected phenoxyl radical ArO. while the normal nitroxide spin adduct was seen alone upon 
addition of carbon-centered radicals [36].
 
Our EPR data therefore suggest that the phenoxyl radicals 
arising from nitrones 4a−i, which have a lower steric protection, decay too fast to allow EPR detection 
and are not spin trapped. 
 
EPR Measurement of NO Release from PPNs. We then turned our attention to the potential NO-
releasing properties of PPNs in water and for this purpose we used the water soluble nitrosyl-Fe(II) 
complex of N-methyl-D-glucamide dithiocarbamate (MGD), [Fe(II)−MGD2] as a trap for NO. When a 
saturated aqueous solution of 4-Cl-PPN 4r (pH 6.58) was UV-photolyzed in the dark for 10 min in the 
presence of a solution of [Fe(II)−MGD2] prepared as described in the Experimental Section, the 
characteristic EPR triplet of [Fe(II)−MGD2−NO] [37] was detected at room temperature, with aN = 
1.269 mT and giso = 2.0418, identical to that recorded from 20 mM sodium nitrite (NaNO2), an inorganic 
NO donor. The NO-derived EPR triplet from 4r increased with photolysis time, reaching a maximum 
after ~1 h (final pH 6.56), while additional signals appeared (Figure 4A), corresponding to an alkyl 
radical adduct (aN = 1.464; aH = 0.297; aP = 4.349 mT; g = 2.0071) and a decomposition triplet (aN = 
1.623 mT; g = 2.0069). The same radical mixture with similar EPR intensities was observed when 
aqueous 4r was allowed to stand in ambient light for 4.5 h (not shown), consistent with a spontaneous 
NO release in aqueous environment. 
To systematically compare the magnitude of this NO-releasing property among tested nitrones, they 
were photolyzed for 70 min under complete solubility conditions (i.e., at 20 mM) and the relative 
[Fe(II)−MGD2−NO] concentrations and pH variation were compared to that 0.1 mM sodium 
nitroprusside dihydrate (SNP), a widely used NO donor. As shown in Figure 4B, NO release 
significantly varied with PPNs structure, and the greatest effect was found for nitrones 4q,j,p whose aryl 
groups bear the bulkiest ortho-substituents. During most experiments a typical benzaldehyde’s smell 
developed in test tubes and maximal pH variations were within instrumental error (i.e., 0.03 pH units). 
PBN was the weakest NO donor while decomposition of SNP in water, even at a 200-fold lower 
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concentration, yielded 2 × 10
4
 times greater amounts of NO relative to the best PPNs. On the basis of 
the reported mechanisms of NO release from aqueous spin traps, including PBN [17,37], a similar 
behavior for PPNs can be postulated where the C(1)−N(8) bond of the primarily formed hydroxylamine 
5 cleaves to give a benzaldehyde and the β-phosphorylated nitroso compound 6 as the actual photolytic 
source of NO (Figure 5). In agreement, performing the NO-trapping assay on synthesized nitroso 6 (0.1 
M) allowed to detect the Fe(II)-nitrosyl complex after only 10 min of photolysis but in this case a very 
strong triplet (aN = 1.612; a13-C = 0.60 mT; g = 2.0066) was the major EPR signal. To rule out any 
additional role of the phosphorylated moiety in NO-donation by PPNs, we found no EPR signal when 
the assay was carried out on the β-phosphorylated amino analogue 7 (Figure 5, inset). 
Altogether, the increased NO-releasing power for the bulkiest PPNs and a mechanism such as that 
shown in Figure 5 suggest a possible correlation between substitution at C(3), C(7) and the C(1)−N(8) 
bond length of the key intermediate 5, which should cleave more easily as this bond is lengthened. 
Figure 4B shows the C(1)−N(8) distances determined after modeling and optimization of the geometry 
using HyperChem 8.0 software (Autodesk, Inc.). Although the hydroxylamines from all ortho-
substituted PPNs had signifiantly longer C(1)−N(8) bonds even for small OH groups, the relationship 
with trapped NO amounts was not straightforward, as exemplified by PPN (Figure 4B). Experimental 
studies [38] and density functional theory (DFT) calculations [39,40] have established β-cleavage of the 
C−N bond as a major step leading to NO release and affecting stability of O2.
-
 and HO. nitroxide spin 
adducts of phosphorylated cyclic nitrones. Regarding linear PPNs, a DFT study has proposed alternative 
mechanisms for the unimolecular decomposition of 4-OH-PPN-OOH adduct involving intramolecular 
H-bonds and nonbonding interactions [32], yet without excluding this may ultimately proceed via NO 
release. 
 
Antioxidant Activity of PPNs Derivatives. The antioxidant properties of PPNs were assessed using 
three standard assays, i.e., scavenging of 1,1’-diphenyl-2-picrylhydrazyl (DPPH) in methanol, 
determination of the total reactive antioxidant potential (TRAP) in DMSO (2%)-supplemented Tris-HCl 
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buffer (pH 7.4) and quenching of O2.
-
 in glycine buffer (pH 10) [41-43]. As most PPNs did not yield 
PPNs-OOH EPR signals upon xanthine oxidase-based generation of O2.
-
 (see above), we also 
investigated whether this enzyme is inhibited by these nitrones. Experimental details for all antioxidant 
studies are provided in Supporting Information. The results are shown in Table 4 and are compared to 
the parent PBN and PPN nitrones, four natural product-based phenolic acids whose aromatic framework 
was used to build compounds 4d,g−i, and two standard antioxidants, the flavonol quercetin and Trolox, 
a water-soluble vitamin E analogue. 
DPPH reducing capacity of PPNs. Measuring the decay at 517 nm of the stable nitrogen radical 
DPPH in a polar organic solvent has been routinely used to probe the radical scavenging property of 
phenolic antioxidants which can react with the divalent N atom of DPPH [44]. The mechanism involves 
reduction of DPPH by a formal H-atom transfer reaction from the aromatic hydroxy groups [10,41,44]. 
Accordingly, mixing DPPH (0.13 mM in methanol) for 3 min with PBN, PPN or its non-phenolic 
derivatives 4j−q (5 µM−1 mM) did not result in a significant absorption decrease, giving EC50 values > 
1 mM (defined as the concentration necessary to halve DPPH concentration). Among phenolic PPNs, 
the strong DPPH scavenging activities of gallic and caffeic acids, both incorporating a 3,4-OH pattern, 
were well translated to their analogues 4g and 4d, respectively, with EC50 ~ 10−20 µM similar to that of 
Trolox and quercetin. Introduction of one or two methoxy substituents to the 4-OH phenolic structure, 
such as in nitrones 4h and 4i, slightly decreased the activity in the assay, which yet remained 4−5 times 
lower than that observed in the analogues ferulic and sinapic acids, respectively. Lastly, 
monohydroxylated PPNs 4a−c and the other phenolic nitrones lacking the 3,4-OH catechol pattern 4e,f 
did not significantly scavenge DPPH. The present results are consistent with general structural features 
promoting the antioxidant activity of phenolic acids [25] and literature data reporting that DPPH 
scavenging activity of hydroxycinnamic acid derivatives is enhanced by the presence of either a 3,4-OH 
pattern [25,45] or electron donors such as methoxy groups in ortho position to a 4-OH group [46]. 
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TRAP Assay. To determine the TRAP (expressed in Trolox equivalents (TE), i.e., TRAP = 1 for 
Trolox) of PPNs (1−30 µM), we used the concentration-dependent inhibition of luminol (13 µM) 
chemiluminescence as a probe of ROO. radical formation during the decomposition of 2,2'-azobis(2-
amidinopropane) dihydrochloride (AAPH, 150 mM) at 37 °C. If OH groups in phenolic antioxidants are 
privileged targets for AAPH-derived peroxyl radicals [10,25,41,44], additional trapping at the nitrone 
site of PPNs may synergistically participate in the TRAP. However, PBN, PPN and all non-phenolic 
PPNs (with the exception of the ester nitrone 4o) had virtually no TRAP, a result also reported for PBN 
and some non phenolic N-alkyl analogues [47].
 
Based on TRAP results on phenolic PPNs, the good 
antioxidant properties of caffeic, gallic, ferulic and sinapic acids (TRAP = 1.18−2.73 TE) were quite 
completely preserved in their PPNs analogues 4b, 4g, 4h and 4i, respectively (TRAP = 1.44−2.22 TE), 
in correlation with the presence of a para-OH (Table 4). Regarding phenolic PPNs, our findings that (i) 
they all showed reactivity with AAPH-derived ROO., and (ii) no spin adducts were detected upon 
reaction with HOO. in aqueous medium (see above), we could conclude that these PPNs should act as 
classical antioxidants in oxidative stress situation. However one must consider that in buffers PPNs-
OOH nitroxides have relatively short half-lives [48] and that the addition rate of the bulky AAPH-
derived peroxyl radical at the hindered nitrone site of PPNs is likely too low to compete with H-atom 
abstraction. 
Superoxide quenching activity. First, the xanthine oxidase inhibiting activity of PPNs and four parent 
phenolic acids was assessed using a reported procedure [49]. Each compound (ranging 1−100 µM) was 
incubated at 37 °C for 30 min with a mixture of xanthine (50 µM)-xanthine oxidase (1.25 mU/mL) in 
DMSO (1%)-supplemented PBS (200 mM, pH 7.5) and uric acid formation was monitored 
spectrophotometrically. Under these conditions, none of the tested compounds interfered with uric acid 
formation (not shown), whereas in this assay known xanthine oxidase inhibitors such as allopurinol and 
quercetin showed IC50 values of 0.95 ± 0.07 µM and 3.50 ± 0.14 µM, respectively. Our results are in 
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agreement with the reported weak activity of caffeic, gallic and sinapic acids (at concentrations up to 
100 µM) toward xanthine oxidase [50].
 
Next, O2.- inhibition properties of the new compounds, selected phenolic acids and antioxidants 
Trolox and quercetin (within the range 0.1 µM−40 mM) were evaluated at 25 °C in DMSO (0.1%)-
supplemented glycine buffer (6.25 mM, pH 10.1) by an improved method
43
 using allopurinol (12.5 µM)-
xanthine oxidase (0.458 mU/mL) as the free radical generator and lucigenin chemiluminescence as the 
detector. Under basic conditions, O2.- may undergo two competitive reactions in the presence of PPNs, 
i.e., (i) addition at the electrophilic carbon of the nitrone function (that is the spin trapping reaction) 
and/or (ii) electron transfer from the phenolate groups [10,25,45], in the case of antioxidant-based PPNs. 
Consistent with the spin trapping mechanism, IC50 values < 60 µM were obtained for non-phenolic 
PPNs 4j−p and the most active within this set of nitrones were those bearing electron-withdrawing 
substituents at ortho or para position (Table 4). Indeed, such attractive inductive effects, which could 
accelerate the rate of O2.- addition by increasing the electrophilicity of the carbon of the nitrone group, 
may also explain the 10-fold lower activity found for PBN vs PPN, which bears an electronegative β-
diethoxyphosphoryl group. Thus, both attractive effects of (EtO)2P(O) moiety and aromatic substituents 
on O2.- inhibition superimposed in nitrones 4j−p, leading to a 7−90 increase in activity vs PPN. 
Moreover, the β-phosphorylated secondary amine 7 (Figure 5, inset) showed no activity (IC50 > 40 mM) 
in the assay, further confirming that the nitrone function is an active site for scavenging. Finally, 2,6-
Me-PPN 4q exhibited a poor scavenging effect (IC50 ~ 350 µM) as a possible consequence of the slow 
rate of radical addition at the sterically-hindered nitrone site (Figure 2B). 
Of the phenolic PPNs 4a−i tested against O2.-, 3,5-OH-PPN 4e was the less active, being however 
twice better than PPN (Table 4). Hydroxylated PPNs showing the best activities were substituted at the 
ortho or para position (e.g., in 4a,c) and, as in the DPPH assay above, compounds having a 3,4-OH 
pattern (i.e., 4d,g) exhibited antioxidant properties equivalent to their structural analogues (caffeic and 
gallic acids, respectively) and references (Trolox and quercetin). In contrast, 3-MeO substituted 4i was 
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found less active than sinapic acid while 4h and ferulic acid demonstrated similar effects. It is 
noteworthy that at the basic pH of the assay hydroxylated PPNs predominate in the phenolate anionic 
form, a situation reported to favor O2.- quenching by electron transfer [45]. However, this does not rule 
out that part of the inhibition effect seen here reflects actual O2.- trapping at the nitrone site. 
 
PPNs Cytotoxicity on A549 Cells and Lipophilicity. The cytotoxic properties of PPN, selected 
PPNs derivatives, four related phenolic acids, and PBN were screened against A549 human lung 
carcinoma cells by measuring lactate dehydrogenase (LDH) release and cell ATP content, and by 
running FMCA and MTT cell viability and metabolic activity assays (see details in Supporting 
Information). Cells were incubated in DMEM containing 0.5% DMSO as vehicle for 1−48 h with nine 
PPNs that showed the highest overall antioxidant potency (Table 4) and/or NO-releasing property 
(Figure 4B) in comparison to less active nitrones such as 4c, 4e, 4l, 4n and 4o at a range of 
concentrations relevant to general pharmacological usage (i.e., 10 µM−1 mM) or compatible with EPR 
spin trapping (i.e., 10−30 mM). Prior to experiments we checked that addition of 0.5% DMSO in 
DMEM had no impact vs DMEM alone on LDH release, ATP content decrease and loss of viability of 
confluent cells after incubation for 48 h (not shown). 
Using an incubation time of 6 h and concentrations up to 1 mM, none of the tested compounds 
demonstrated cytotoxicity, i.e., LDH leakage (overall range of 29 ± 2.6−32.6 ± 1.9 U/L in extracellular 
medium) did not exceed 2% of total LDH activity of untreated cells (being 1979 ± 240 U/L), while ATP 
content was not significantly altered (overall range of 4.93 ± 0.25−6.12 ± 0.19 µM vs 5.69 ± 0.41 µM in 
control cells, P > 0.5 by one-way ANOVA). Since FMCA and MTT assays showed a 95−99% 
preservation of cell viability following treatment with PPNs for 6 h (not shown), a common nontoxic 
concentration of 200 µM was adopted in experiments on isolated rat aortic rings (see below). 
Table 5 (left panel) summarizes IC50 values obtained upon incubating cells for 48 h with an extended 
concentration range of 0.01−30 mM. Gallic and caffeic acids decreased cell viability by 50% at 
concentrations as low as ~370 µM and ~630 µM, respectively, while a ca. 8−10-fold lower cytotoxic 
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effect was observed with the methoxylated ferulic and sinapic acids. Whereas this same trend was found 
among the PPNs derivatives 4d,g−i of these phenolic acids, the nitrones were found comparatively less 
cytotoxic, e.g., the mean IC50 was ~14 mM for 4i and only ~5 mM for sinapic acid. Of interest, the mean 
IC50 value for PBN (~9 mM), close to those reported in bovine aortic endothelial cells (9.4 mM) [51] or 
3T3 murine fibroblasts (7 mM) [52], slightly improved for PPN (~13 mM) despite this latter nitrone was 
more lipophilic (see computed AlogP values in Table 4). In this regard, literature reported a connexion 
between cytotoxicity of phosphorylated nitrones and lipophilicity-driven cell penetration and/or 
disturbance of membrane integrity [51-54], a trend confirmed in this study for PPNs such as 4-CO2Et-
PPN 4o, 2-CF3-PPN 4p or 2,6-Me-PPN 4q having AlogP values higher than that of PPN (i.e., 1.65). In 
marked contrast, the most hydrophilic antioxidant-based nitrones 3,4-OH-PPN 4d and 3,4,5-OH-PPN 
4g, which demonstrated the best antioxidant potency (Table 4), were the most cytotoxic of the tested 
PPNs (Table 5, left panel). Consistent with data showing that methoxylation of polyhydroxyphenols 
results in decreased cytotoxicity [55], a significant increase in IC50 values was achieved by nitrones 4-
OH-3-OMe-PPN 4h and 4-OH-3,5-OMe-PPN 4i although they are more lipophilic than their non 
methoxylated analogues 4d,g, respectively. In terms of a possible mechanism underlying the cytotoxicity 
of the new antioxidant, phenolic-based PPNs, the detrimental prooxidant action of intermediately 
formed ArO. radicals on intracellular pool and/or key signalling enzymes can be hypothesized, similar to 
that proposed for flavonoids [55]. Based upon this mechanism of action, studies are currently underway 
to examine the anti-proliferative and apoptotic properties of anticancer drugs constructed from phenolic 
antioxidants such as ferulic and caffeic acids [56]. Unrelated to its lipophilicity 2-NO2-PPN 4j was 
found 6-fold more cytotoxic than PPN, a result not surprising given the known toxicity of nitroso spin 
traps [51] and nitroaromatic compounds. 
When cells were exposed to PPNs for 48 h the mean IC50 values found for each tested compound 
using FMCA, ATP and MTT assays showed little dispersion, suggesting the cytotoxicity seen here is 
mainly due to alteration of intracellular enzymatic and mitochondrial functions that caused cell death. In 
parallel, however, only a modest LDH leakage was observed for all PPNs (5−25% of total baseline 
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intracellular content) as concentrations causing cell death were applied. Under these conditions the 
calculated IC50 values for the LDH assay are overestimated, showing an apparent increase of viability as 
compared to the above assays, giving false-positive results. It is thus possible that PPNs-induced 
membrane damage and/or necrosis is low compared to intracellular alterations or, more likely, that 
released LDH was degraded after 48 h incubation to reach undetectable levels. 
In the last step of the cytotoxicity study, we looked for concentration and incubation conditions 
allowing PPNs to be safely used for EPR-spin trapping studies in stressed cells. When A549 cells were 
exposed for 3 h to 15 mM of various nitrones, the MTT assay showed no significant decrease in cell 
viability compared to untreated cells (overall range of 97.1 ± 1.2−101.3 ± 1.9 %, P > 0.5 by one-way 
ANOVA). However, a few nitrones led to a decrease of total intracellular LDH indicating they 
significantly impact cell integrity (i.e., when ∆ > 20%; Table 5), particularly the antioxidant 3,4-OH-
PPN 4d and 3,4,5-OH-PPN 4g, and even more the nitro derivatives 4j,l. When a short incubation time 
was applied, LDH leakage therefore appeared as a good endpoint of early cytotoxicity of PPNs. Using 
this index, we found a minimal cytotoxicity (i.e., ∆ < 5%) for all tested PPNs when incubation time was 
1 h and, according to these data, the safe use of PPNs at 15 mM as EPR probes in cell cultures or aortic 
rings preparations (see below) was considered guaranteed for incubation durations of ~20 min. 
 
NO-Mediated Vasorelaxant Potency and Antioxidant Properties of PPNs in Aortic Ring 
Preparations. To investigate the vascular relaxant potency of a subset of PPNs, we used endothelium-
intact rat aortic rings precontracted with 5 × 10
-6
 M of the α1-adrenoceptor agonist phenylephrine (PE) 
to similar levels. Concentration-response curves to endothelium-independent NO-donor SNP were 
recorded in the presence of nitrones (200 µM) in KH buffer with 0.1% DMSO as cosolvent, allowing 
quantification of the potency half maximal effective concentration (pEC50) and relaxation efficacy 
(Rmax). 
Most of the examined compounds improved concentration-dependent vasorelaxing responses to SNP, 
with full efficacy as shown by Rmax values ~100%. Consistent with the implication of NO in the 
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observed vasorelaxing effect, the strongest in vitro NO-donating PPNs 4j,p,q (see Figure 4B) 
significantly enhanced the potency of vasorelaxation to SNP (Table 5). However, the vasorelaxing 
actions of weaker, yet efficient NO donors such as 4a,b were almost comparable to that of PBN, despite 
it releases ~6-times less NO amounts in vitro (Figure 4B). High concentrations of PBN (millimolar 
range) were needed to induce a sustained dose-response relaxation in rat pulmonary arteries contracted 
with PE [57].  Here, a number of PPNs tested at submillimolar doses (i.e., having pEC50 > 8.6), but not 
PBN, demonstrated their remarkable ability to induce a leftward shift of the relaxation curve to SNP 
although it is a far better NO-donor than the nitrones (by at least five orders of magnitude). 
Besides their NO-donating effect, PPNs are endowed with other intrinsic properties that may also 
induce strong vasorelaxation of rings, a feature which could explain the apparent lack of correlation 
between the ease of NO donation and the vasodilation potency. To illustrate, we found that 3,4-OH-PPN 
4d and 3,4,5-OH-PPN 4g significantly improved the relaxant response to SNP by 20% although both 
PPNs are weak NO-donors in vitro (Table 5). To assess if this effect could rely on the decrease of 
vascular basal O2.
-
, the response to SNP was determined in six additional wells in which SOD (30 
U/mL) was preincubated into the ring medium for 30 min before adding PE. A significant increase of 
pEC50 value (9.05 ± 0.03, P < 0.05 vs vehicle) with full efficacy (Rmax = 105%) was observed in these 
rings. Accordingly, improvement in the vasorelaxant effect seen for the antioxidant PPNs 4d,g may be 
an indirect consequence of their good O2.
-
 scavenging properties (Table 4) which preserves 
endothelium-derived NO biodisponibility. This second chemical mechanism by which PPNs may 
improve vasorelaxant response to SNP agrees with previous observations in vessels treated with 
polyphenolic compounds such as quercetin, which strongly enhanced vasodilatation in an endothelium-
independent manner [58,59]. 
A third mechanism underlying PPNs vasorelaxant properties can be postulated from the finding that 
the pEC50 data of the methoxylated 4h,i were similar to that of hydroxylated 4d,g (Table 5) despite they 
are ~100-times less efficient O2.
-
 scavengers (Table 4) and show very weak NO-donating potency 
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(Figure 4B). Indeed, the key structural feature of derivatives 4h,i is a 3-methoxyphenyl group, whose 
presence in the ferulic and sinapic acids structures was reported to confer improved relaxant activity as 
compared to caffeic acid in rat aortic rings [60]. In this connection, a bioactive effect involving 
inhibition of endothelial NADPH oxidase ROS formation was demonstrated for a wide series of 3-
methoxyphenyl substituted flavonoids and phenolics [61].  
On this basis of preserving the endothelium-mediated NO release function under high levels of ROS, 
we speculated that the lead antioxidant-based PPNs emerging from Table 4 should demonstrate 
enhanced efficacy. In additional experiments, aortic rings were first incubated for 10 min with a 
xanthine (0.1 mM)-xanthine oxidase (10 mU/mL) O2.
-
 generator, then precontracted with PE (~10
-6
 M) 
in the presence of either nitrones 4d,g−i, PBN or PPN (all at 200 µM) and the relaxing activity to the 
endothelium-dependent vasorelaxant agent acetylcholine (ACh; 10
-9−10-4 M) was examined. Addition 
of O2.
-
 led to significant endothelial dysfunction (~40% reduction in Rmax to ACh), which was almost 
completely reversed by all tested PPNs, but only to a lesser extent by PBN or PPN (Table 6). 
Compounds 4d,g, which showed the best O2.
-
 scavenging properties (Table 4) and had moderate NO 
releasing properties (Figure 4B), were the most efficient in limiting O2.
-
-induced rightward shift of the 
concentration-response curves to ACh (Figure 6A), which result to the decrease of pEC50 (Table 6). 
Since these latter data strongly implicate the antioxidant properties of PPNs in protecting endothelial 
function upon exogenous ROS formation, we carried out a last series of experiments in aortic rings to 
assess biochemical changes following stimulation of vascular NADPH oxidase to produce high levels of 
O2.
-
. Rings were incubated for 90 min with excess NADPH (1 mM) and the protective effect of eight 
PPNs (200 µM) on protein oxidation was evaluated by assaying tissue protein carbonyl levels with an 
improved procedure [62]. Incubation medium contained diethyldithiocarbamate (DTC; 15 µM) to 
inactivate intracellular SOD [63].  Addition of NADPH to the incubation medium resulted in a burst of 
protein carbonyls, which was expectedly reversed by the NADPH oxidase inhibitor diphenylene 
iodonium (DPI). Treatment with PPNs, but not PBN, achieved a variable, significant inhibition of ROS-
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induced elevation of protein oxidation (Figure 6B), with the four antioxidant-based compounds 4d,g−i 
having a better efficacy than nitrones 4b,e,q which have shown a poorer global antioxidant effect in 
vitro (Table 4). However, this correlation between antioxidant effects and apparent limitation of lipid 
peroxidation of rings was not observed for 4-OH-PPN 4c which significantly inhibited protein carbonyls 
formation despite its moderate TRAP value and lack of reactivity toward DPPH. Some slight 
discrepancy in the inhibition results could also be seen between the methoxyphenyl-substituted 
compounds 4h,i and the strong antioxidant polyhydroxylated derivatives 4d,g (Figure 6B), suggesting 
other factors may be involved in the in vivo effects of nitrones, such as lipophilicity or cell permeation. 
Other mechanisms such as reversion of eNOS dysfunction have been proposed to explain the protection 
of endothelial integrity by nitrones [include new 64 and 65]. On the other hand, hydrolysis products of 
PPNs such as benzaldehydes and hydroxylamine 5 (Figure 5) may exert stronger antioxidant effects. 
This has been reported for N-tert-butylhydroxylamine which displays powerful O2.
-
 inhibition at 
mitochondrial level and is considered the major active species mediating the anti-senescence action of 
PBN [64 (will be 66)]. 
 
Spin Trapping in Aortic Rings Undergoing Oxidative Stress. With the protein carbonyls data in 
hand, we sought (i) to validate PPNs as efficient in vivo EPR probes by characterizing free radical 
species released in the incubation medium of rings preparations exposed to NADPH (1 mM) as 
described above, and (ii) to test if EPR signal intensities may bear witness to the antioxidant role of 
nitrones as shown in Figure 6B. 
After having stimulated the rings for 60 min with NADPH (1 mM) in the presence of antioxidant 
PPNs (200 µM) as described above, the incubation medium was renewed with a mixture of NADPH (1 
mM) and each PPNs (15 mM) in buffer containing 1% DMSO as cosolvent, incubation was prolonged 
for 20 min at 37 °C and samples were assayed by EPR at room temperature following a freeze/thawing 
sequence. For PPNs 4b−e and 4g−i, with the exception of PBN, easily detectable EPR spectra 
characteristic of PPNs-CH3 adducts (Table 2) were obtained in the rings supernatants, the signal being 
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abolished when either DMSO or NADPH are omitted, or upon addition of DPI to the complete 
incubation system (Figure 7A). In most experiments, computer simulation of the EPR signals revealed 
decomposition adducts representing < 10% of the total signal. Our NADPH/NADPH oxidase inhibition 
data strongly suggest that trapped methyl radicals seen here are formed secondary to O2.
-
 which gives 
almost undetectable PPNs spin adducts in buffers. Moreover, the fact that DMSO was required to obtain 
the PPNs-Me signals indicates HO. radicals were formed (see EPR section). Indeed a DMSO-assisted 
spin trapping involving linear nitrones such as PBN has been shown a useful technique to specifically 
evidence hydroxyl radical production in vivo [65]. 
Upon NADPH stimulation of rings, high levels of O2.
-
 and/or H2O2 are generated by membrane 
located endothelial and vascular NAPDH oxidases [66], consecutively leading to HO. formation [67].  
In our indirect radical-trapping system, we expected to get lower EPR signals for nitrones having at least 
two available sites for HO. addition, i.e., for antioxidant PPNs. Figure 7B reveals that the mean PPNs-
CH3 EPR signal intensities show apparent inverse correlation with antioxidant properties of Table 4 and 
with protein carbonyl contents of Figure 6B. Finally, to account for the reliability of PPNs adduct 
concentrations of freeze/thawed samples, we recorded the decay of EPR signal intensities of chemically 
formed PPNs-CH3 adducts after 4 days of storage in liquid nitrogen. While the concentrations of thawed 
methyl radical adducts of PBN and PPN decayed upon by 25% and 30%, respectively, they decreased by 
only < 5% for the other tested PPNs (not shown). Regardless of the comparative kinetics of the reactions 
of HO. at the phenolic sites vs DMSO, and stability parameters of PPNs-CH3 adducts, these data 
highlight the behavior of phenolic acids-based PPNs 4d,g−i as dual antioxidants and EPR probes, which 
should be preferred to PBN or PPN which may yield underestimated quantitative results on ROS 
formation in vivo. 
 
Conclusions 
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In summary, we have documented the versatile synthesis of PPNs, a series of new diethoxyphosphoryl 
substituted derivatives of α-phenyl-N-tert-butyl nitrone having a variably substituted aromatic ring, 
constructed on a natural phenolic antioxidant scaffold or which brings about steric constraint. These 
PPNs were subjected to a complete panel of in vitro (EPR spin trapping, antioxidant assays and NO-
donating properties) and in vivo (cytotoxicity, vasorelaxant effect and protection against ROS-induced 
vascular protein oxidation) testing. Lead hybrid PPNs 4d and 4g−i bearing an aromatic structure close to 
that of caffeic, gallic, ferulic and sinapic acids emerged as non-toxic, moderately-lipophilic potential 
alternatives to PBN in pharmacological studies relevant to vascular tone control. 
 
Experimental Section 
 
Chemistry. General Methods. Starting materials, reagents and solvents were from Sigma-Aldrich 
(Saint Quentin Fallavier, France), Fluka, SDS and Acros Organics (Fisher Scientific, Illkirch, France) 
and were of analytical grade quality. 
1
H and 
13
C NMR spectra were recorded on a Bruker DPX-300 (at 
300 MHz) or Bruker Avance III nanobay-400 (at 400 MHz) spectrometers in CDCl3 or DMSO–d6 
solution (from Euriso-Top, Saint Aubin, France). Chemical shifts (δ) for 1H and 13C are reported in parts 
per million (ppm) relative to tetramethylsilane (TMS) as internal standard and coupling constants (J) are 
given in Hertz (Hz). Multiplicity abbreviations used are as follows: br, broad; s, singlet; d, doublet; dd, 
doublet of doublets; t, triplet; dt, doublet of triplets; td, triplet of doublets; m, multiplet. Melting points 
were obtained using a Büchi Melting Point B-540 apparatus and are not corrected. High-resolution mass 
spectrometry (HRMS) in electron spray ionization (ESI) was performed at the Spectropole (Analytical 
Laboratory) at Campus St. Jérôme (Marseille, France) on a Q-STAR Elite instrument (Applied 
Biosystems, USA). Purity of final compounds was determined at 254 nm by HPLC (Agilent 1200 series, 
USA) using a C18 column (Beckman Coulter Inc., USA) and was 95% or greater. 
 
Synthesis of diethyl-2-aminopropan-2-ylphosphonate (1). Being a starting material in all syntheses, 
this compound was prepared in large scale. Acetone (220 mL, 3 mol, 2 eq) was bubbled in continuum 
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with dry ammonia at 5 °C for 15 min. Diethylphosphite (192 mL 1.5 mol) was added dropwise and the 
solution was stirred at 5 °C for 2 h. After removing the ammonia-bubbling, the mixture was stirred at 
room temperature overnight. The excess acetone was evaporated under reduced pressure and the residue 
was treated with 20% aqueous NaOH (20 mL) and chloroform (100 mL). The organic layer was 
separated, dried over MgSO4 and filtered. The solvent was removed under reduced pressure to give 1 as 
a colourless oil (438 g, 75%): 
1
H NMR (300 MHz, CDCl3) δ 4.12−4.01 (m, 4H, 2 × OCH2CH3), 
1.30−1.16 (m, 12H); 13C NMR (75 MHz, CDCl3) δ 62.3 (OCH2CH3), 62.2 (OCH2CH3), 49.0 (d, J = 
147.7 Hz, C(CH3)2), 25.1 (d, J = 3.8 Hz, C(CH3)2), 16.6 (OCH2CH3), 16.5 (OCH2CH3); 
31
P NMR (121 
MHz, CDCl3) δ 32.39. 
Synthesis of diethyl-2-nitropropan-2-ylphosphonate (2). To a vigorously stirred mixture of 1 (20 g, 
0.1 mol) and MgSO4 (24 g, 0.2 mol, 2 eq) in acetone/water (150:20 mL) and water (20 mL) was added 
KMnO4 (32 g, 0.2 mol, 2 eq) portionwise. The mixture was heated at 50-55 °C for 1 day, cooled at room 
temperature and filtered. The cake was washed with Et2O, the filtrate was concentrated and the residue 
was extracted with CH2Cl2 (3 × 50 mL). The organic layers were gathered, dried over MgSO4, filtered 
and concentrated to yield 2 as a pale yellow oil (16 g, 70%): 
1
H NMR (300 MHz, CDCl3) δ 4.11 (m, 4H, 
2 × OCH2CH3), 1.72 (d, J = 14.5 Hz, 6H, C(CH3)2), 1.24 (t, J = 7.1 Hz, 6H, 2 × OCH2CH3); 
13
C NMR 
(75 MHz, CDCl3) δ 86.0 (d, J = 151.30 Hz, C(CH3)2), 64.0 (d, J = 7.1 Hz, OCH2CH3), 22.6 (d, J = 1.0 
Hz, C(CH3)2), 16.0 (d, J = 6.0 Hz OCH2CH3); 
31
P NMR (121 MHz, CDCl3) δ 17.24. 
Synthesis of diethyl-2-(hydroxyamino)propan-2-ylphosphonate (3). Compound 2 (4.0 g, 18 mmol, 
1.7 eq) and NH4Cl (0.58 g, 10.8 mmol) were dissolved in water (20 mL) at room temperature under 
vigorous stirring. The mixture was cooled at −10 °C and Zn powder (2.4 g, 37 mmol, 3.4 eq) was added 
portionwise. The mixture was stirred at room temperature for 2 h and at 50−55 °C for 1 h, cooled to 
room temperature and filtered. The filtrate was extracted with CH2Cl2 (3 × 20 mL), the organic layers 
were gathered, dried over MgSO4, filtered and concentrated under vacuum. The residue was precipitated 
in hexane (20 mL) to yield 3 as colourless crystals (1.2 g, 53%), mp 62.3 °C (litt. [68] 56−57 °C): 1H 
NMR (300 MHz, CDCl3) δ 3.93 (m, 4H, 2 × OCH2CH3), 1.11 (d, J = 15.4 Hz, 6H, C(CH3)2), 1.10 (t, J = 
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7.2 Hz, 6H, 2 × OCH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 61.6 (d, J = 7.1 Hz, OCH2CH3), 57.6 (d, J = 
146.4 Hz, C(CH3)2), 20.0 (d, J = 1.6 Hz, C(CH3)2), 16.0 (d, J = 6.0 Hz, OCH2CH3); 
31
P NMR (121 
MHz, CDCl3) δ: 30.69. 
General procedure for the synthesis of PPNs (4a−4r). A mixture of 3 (4 mmol, 1 eq) and the 
corresponding benzaldehyde (4 mmol, 1 eq) in THF or DCE (30 mL) was stirred at 100 °C for 4 h in the 
presence of MgSO4 (spatula tip). The mixture was allowed to cool at room temperature and filtered. The 
filtrate was concentrated under vacuum and the residue was purified by either precipitation or 
crystallization from a defined solvent. 
2-(Diethoxyphosphoryl)-N-(benzylidene)propan-2-amine oxide (PPN). The title compound was 
obtained from 3 (400 mg, 1.9 mmol) and benzaldehyde (200 mg, 1.9 mmol) in THF (20 mL) as a yellow 
pale oil after SiO2-chromatography (CHCl3/CH3CN, 50:50) (65 mg, 12%): 
1
H NMR (400 MHz, CDCl3) 
δ 8.20 (dt, J = 7.5 and J = 1.8 Hz, 2H, H-2), 7.68 (d, J = 2.7 Hz, 1H, HC=NO), 7.34 (d, J = 7.5 Hz, 2H, 
H-3), 7.33 (br d, 1H, H-4), 4.13 (m, 4H, 2 × OCH2CH3), 1.79 (s, 3H, C(CH3)2), 1.74 (s, 3H, 
C(CH3)2),1.25 (t, J = 7.0 Hz, 6H, 2 × OCH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 133.2 (d, J = 2.0 Hz, 
HC=NO), 130.7 (d, J = 1.6 Hz, C-1), 130.4 (C-4), 129.0 (C-3), 128.4 (C-2), 72.8 (d, J = 154.6, 
C(CH3)2), 63.4 (d, J = 7.2 Hz, OCH2CH3), 23.3 (C(CH3)2), 16.4 (d, J = 6.1 Hz, OCH2CH3); 
31
P NMR 
(162 MHz, CDCl3) δ 22.65. HRMS-ESI: calcd for C14H23NO4P
+
 [M+H]
+
 300.1359, found 300.1360. 
2-(Diethoxyphosphoryl)-N-(2-hydroxybenzylidene) propan-2-amine oxide (2-OH-PPN; 4a). The title 
compound was obtained from 3 (400 mg, 2.0 mmol) and 2-hydroxybenzaldehyde (230 mg, 2.0 mmol) in 
DCE (12.5 mL) as a yellow oil (0.3 g, 50%): 
1
H NMR (300 MHz, CDCl3) δ 7.90 (d, J = 2.8 Hz, 1H, 
HC=NO), 7.39 (td, J = 8.0 and J = 1.5 Hz, 1H, H-4), 7.15 (dd, J = 7.9 and J = 1.5 Hz, 1H, H-6), 6.96 (br 
d, J = 8.0 Hz, 1H, H-3), 6.86 (br t, J = 8.0 Hz, 1H, H-5), 4.23 (m, 4H, 2 × OCH2CH3), 1.88 (s, 3H, 
C(CH3)2), 1.83 (s, 3H, C(CH3)2), 1.35 (t, J = 7.1 Hz, 6H, 2 × OCH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 
159.7 (C-2), 140.4 (d, J = 6.0 Hz, HC=NO), 134.0 (C-6), 132.5 (C-4), 120.2 (C-5), 119.0 (C-3), 116.8 
(C-1), 71.4 (d, J = 155.2, C(CH3)2), 63.7 (d, J = 7.1 Hz, OCH2CH3), 23.4 (C(CH3)2), 16.4 (d, J = 6.0 Hz, 
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OCH2CH3); 
31
P NMR (121 MHz, CDCl3) δ 21.91. HRMS-ESI: calcd for C14H23NO5P
+
 [M+H]
+
 
316.1308, found 316.1308. 
2-(Diethoxyphosphoryl)-N-(3-hydroxybenzylidene)propan-2-amine oxide (3-OH-PPN; 4b). The title 
compound was obtained from 3 (500 mg, 2.4 mmol) and 3-hydroxybenzaldehyde (290 mg, 2.4 mmol) in 
DCE (15 mL) as pink crystals from a mixture Et2O/n-hexane, 50:50 (0.33 g, 44%), mp 101.2 °C: 
1
H 
NMR (400 MHz, CDCl3) δ 8.36 (br s, 1H, H-2), 7.74 (d, J = 2.8 Hz, 1H, HC=NO), 7.31 (br d, J = 8.0 
Hz, 1H, H-6), 7.19 (t, J = 8.0 Hz, 1H, H-5), 6.91 (dd, J = 8.0 and J = 2.1 Hz, 1H, H-4), 4.23 (m, 4H, 2 × 
OCH2CH3), 1.87 (s, 3H, C(CH3)2), 1.82 (s, 3H, C(CH3)2), 1.33 (t, J = 7.2 Hz, 6H, 2 × OCH2CH3); 
13
C 
NMR (75 MHz, CDCl3) δ 157.1 (C-3), 135.5 (d, J = 6.0 Hz, HC=NO), 131.0 (d, J = 1.7 Hz, C-1), 129.3 
(C-5), 121.7 (C-6), 118.7 (C-2), 115.6 (C-4), 72.7 (d, J = 155.2, C(CH3)2), 63.7 (d, J = 7.2 Hz, 
OCH2CH3), 23.1 (C(CH3)2), 16.4 (d, J = 5.5 Hz, OCH2CH3); 
31
P NMR (121 MHz, CDCl3) δ 23.19. 
HRMS-ESI: calcd for C14H23NO5P
+
 [M+H]
+
 316.1308, found 316.1307. 
2-(Diethoxyphosphoryl)-N-(4-hydroxybenzylidene)propan-2-amine oxide (4-OH-PPN; 4c). The title 
compound was obtained from 3 (600 mg, 2.85 mmol) and 4-hydroxybenzaldehyde (350 mg, 2.85 mmol) 
in THF (20 mL) as colourless crystals from Et2O (0.63 g, 70%), mp 138.9 °C (litt. [32] 138.5−139.5 
°C): 
1
H NMR (300 MHz, CDCl3) δ 9.41 (br s, 1H, OH), 7.88 (d, J = 8.6 Hz, 2H, H-2), 7.37 (br s, 1H, 
HC=NO), 6.75 (d, J = 8.6 Hz, 2H, H-3), 4.27 (m, 4H, 2 × OCH2CH3), 1.84 (s, 3H, C(CH3)2), 1.79 (s, 
3H, C(CH3)2), 1.37 (t, J = 7.1 Hz, 6H, 2 × OCH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 159.8 (C-4), 133.4 
(d, J = 6.6 Hz, HC=NO), 131.4 (C-2), 121,8 (d, J = 1.0, C-1), 115.7 (C-3), 72.6 (d, J = 159.0, C(CH3)2), 
61.5 (d, J = 7.1 Hz, OCH2CH3), 22.3 (d, J = 1.0 Hz, C(CH3)2), 16.4 (d, J = 6.0 Hz, OCH2CH3); 
31
P 
NMR (121 MHz, CDCl3) δ 23.96. HRMS-ESI: calcd for C14H23NO5P
+
 [M+H]
+
 316.1308; found 
316.1311. 
2-(Diethoxyphosphoryl)-N-(3,4-dihydroxybenzylidene)propan-2-amine oxide (3,4-OH-PPN; 4d). The 
title compound was obtained from 3 (500 mg, 2.4 mmol) and 3,4-dihydroxybenzaldehyde (400 mg, 2.4 
mmol) in DCE (20 mL) as a brown solid from Et2O (0.56 g, 70%), mp 172.8 °C: 
1
H NMR (300 MHz, 
DMSO-d6) δ 8.70 (br s, 1H, HC=NO), 7.62 (d, J = 1.7 Hz, 1H, H-2), 7.47 (dd, J = 8.3 and J =1.7 Hz, 
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1H, H-6), 6.77 (d, J = 8.3 Hz, 1H, H-5), 4.07 (m, 4H, 2 × OCH2CH3), 1.69 (s, 3H, C(CH3)2), 1.64 (s, 
3H, C(CH3)2), 1.22 (t, J = 7.0 Hz, 6H, 2 × OCH2CH3); 
13
C NMR (75 MHz, DMSO-d6) δ 144.9 (C-3 and 
C-4), 132.1 (d, J = 6.0 Hz, HC=NO), 123.2 (C-1), 122.6 (C-6), 116.1 (C-2), 115.7 (C-5), 72.5 (d, J = 
156.3, C(CH3)2), 62.8 (d, J = 6.6 Hz, OCH2CH3), 23.4 (C(CH3)2), 16.7 (d, J = 5.5 Hz, OCH2CH3); 
31
P 
NMR (121 MHz, DMSO-d6) δ 23.67. HRMS-ESI: calcd for C14H23NO6P
+
 [M+H]
+
 332.1258, found 
332.1258. 
2-(Diethoxyphosphoryl)-N-(3,5-dihydroxybenzylidene)propan-2-amine oxide (3,5-OH-PPN; 4e). The 
title compound was obtained from 3 (600 mg, 2.85 mmol) and 3,5-dihydroxybenzaldehyde (0.35 g, 2.85 
mmol) in DCE (20 mL) as a white solid from CH2Cl2 (0.45 g, 55%), mp 180.2 °C: 
1
H NMR (300 MHz, 
DMSO-d6) δ 9.34 (br s, 2H, OH), 7.66 (d, J = 2.4 Hz, 1H, HC=NO), 7.24 (d, J = 2.2 Hz, 2H, H-2), 6.29 
(t, J = 2.2 Hz, 1H, H-4), 4.08 (m, 4H, 2 × OCH2CH3), 1.71 (s, 3H, C(CH3)2), 1.66 (s, 3H, C(CH3)2), 1.23 
(t, J = 7.1 Hz, 6H, 2 × OCH2CH3); 
13
C NMR (75 MHz, DMSO-d6) δ 158.4 (C-3), 132.5 (d, J = 1.7 Hz, 
C-1), 132.0 (d, J = 6.0 Hz, HC=NO), 107.4 (C-2), 105.3 (C-4), 72.9 (d, J = 155.7 Hz, C(CH3)2), 62.6 (d, 
J = 6.6 Hz, OCH2CH3), 22.9 (C(CH3)2), 16.3 (d, J = 5.5 Hz, OCH2CH3); 
31
P NMR (121 MHz, DMSO-
d6) δ 23.26. HRMS-ESI: calcd for C14H23NO6P
+
 [M+H]
+
 332.1258, found 332.1259. 
2-(Diethoxyphosphoryl)-N-(2,4-dihydroxybenzylidene)propan-2-amine oxide (2,4-OH-PPN; 4f). The 
title compound was obtained from 3 (500 mg, 2.4 mmol) and 2,4-dihydroxybenzaldehyde (330 mg, 2.4 
mmol) in THF (15 mL) as a white powder from Et2O (0.29 g, 36%), mp 133.3 °C: 
1
H NMR (300 MHz, 
DMSO-d6) δ 7.94 (d, J = 2.4 Hz, 1H, HC=NO), 7.38 (d, J = 8.7 Hz, 1H, H-6), 6.30 (dd, J = 8.3 and J = 
2.2 Hz, 1H, H-5), 6.16 (d, J = 2.2 Hz, 1H, H-3), 4.08 (m, 4H, 2 × OCH2CH3), 1.72 (s, 3H, C(CH3)2), 
1.68 (s, 3H, C(CH3)2), 1.24 (t, J = 7.1 Hz, 6H, 2 × OCH2CH3); 
13
C NMR (75 MHz, DMSO-d6) δ 163.4 
(C-2), 161.4 (C-4), 139.2 (d, J = 5.5 Hz, HC=NO), 135.1 (C-6), 108.9 (C-1), 107.5 (C-5), 104.3 (C-3), 
70.2 (d, J = 155.7, C(CH3)2), 62.8 (d, J = 7.1 Hz, OCH2CH3), 22.8 (C(CH3)2), 16.3 (d, J = 5.5 Hz, 
OCH2CH3); 
31
P NMR (121 MHz, DMSO-d6) δ 22.82. HRMS-ESI: calcd for C14H23NO6P
+
 [M+H]
+
 
332.1258, found 332.1257.  
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2-(Diethoxyphosphoryl)-N-(3,4,5-trihydroxybenzylidene)propan-2-amine oxide (3,4,5-OH-PPN; 4g). 
The title compound was obtained from 3 (500 mg, 2.4 mmol) and 3,4,5-trihydroxybenzaldehyde (400 
mg, 2.4 mmol) in DCE (15 mL) as a brown pale powder from ethylacetate (0.28 g, 35%), mp > 170 °C: 
1
H NMR (400 MHz, DMSO-d6) δ 9.03 (br s, 2H, HO-C-3), 8.70 (b rs, 1H, HO-C-4), 7.52 (d, J = 2.5 
Hz, 1H, HC=NO), 7.38 (s, 2H, H-2), 4.07 (m, 4H, 2 × OCH2CH3), 1.69 (s, 3H, C(CH3)2), 1.64 (s, 3H, 
C(CH3)2), 1.23 (t, J = 7.1 Hz, 6H, 2 × OCH2CH3); 
13
C NMR (75 MHz, DMSO-d6) δ 145.6 (C-3), 136.3 
(C-4), 131.8 (d, J = 6.1 Hz, HC=NO), 121.9 (C-1), 108.9 (C-2), 72.1 (d, J = 156.3 Hz, C(CH3)2), 62.4 
(d, J = 6.6 Hz, OCH2CH3), 23.0 (C(CH3)2), 16.3 (d, J = 5.5 Hz, OCH2CH3); 
31
P NMR (121 MHz, 
DMSO-d6) δ 23.68. HRMS-ESI: calcd for C14H23NO7P
+
 [M+H]
+
 348.1207, found 348.1205. 
2-(Diethoxyphosphoryl)-N-(4-hydroxy-3-methoxybenzylidene)propan-2-amine oxide (4-OH-3-OMe-
PPN; 4h). The title compound was obtained from 3 (500 mg, 2.4 mmol) and 4-hydroxy-3-
methoxybenzaldehyde (0.36 g, 2.4 mmol) in DCE (15 mL) as a white powder from Et2O (0.4 g, 49%), 
mp 128.5 °C: 
1
H NMR (400 MHz, CDCl3) δ 8.57 (d, J = 1.8 Hz, 1H, H-2), 7.68 (d, J = 2.8 Hz, 1H, 
HC=NO), 7.31 (dd, J = 8.3 and J =1.8 Hz, 1H, H-6), 6.94 (d, J = 8.3 Hz, 1H, H-5), 4.21 (m, 4H, 2 × 
OCH2CH3), 3.95 (s, 3H, OCH3), 1.85 (s, 3H, C(CH3)2), 1.83 (s, 3H, C(CH3)2), 1.33 (t, J = 7.0 Hz, 6H, 2 
× OCH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 147.9 (C-3), 146.0 (C-4), 133.7 (d, J = 5.5, HC=NO), 
124.5 (C-6), 123.5 (C-1), 114.3 (C-5), 72.1 (d, J = 154.0, C(CH3)2), 63.4 (d, J = 7.2 Hz, OCH2CH3), 
56.0 (OCH3) 23.2 (C(CH3)2), 16.4 (d, J = 6.0 Hz, OCH2CH3); 
31
P NMR (162 MHz, CDCl3) δ 23.52. 
HRMS-ESI: calcd for C15H25NO6P
+
 [M+H]
+
 346.1414, found 346.1413. 
2-(Diethoxyphosphoryl)-N-(4-hydroxy-3,5-dimethoxybenzylidene)propan-2-amine oxide (4-OH-3,5-
OMe-PPN; 4i). The title compound was obtained from 3 (500 mg, 2.4 mmol) and 4-hydroxy-3,5-
dimethoxybenzaldehyde (290 mg, 2.4 mmol) in DCE (15 mL) as a white solid from ethyl acetate (0.28 
g, 57%), mp 139.2 °C: 
1
H NMR (300 MHz, CDCl3) δ 7.67 (br s, 1H, HC=NO), 7.61 (s, 2H, H-2), 4.20 
(m, 4H, 2 × OCH2CH3), 3.86 (s, 6H, OCH3), 1.77 (s, 3H, C(CH3)2), 1.75 (s, 3H, C(CH3)2), 1.26 (t, J = 
6.9 Hz, 6H, 2 × OCH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 146.6 (C-3), 137.2 (C-4), 134.0 (br s, 
HC=NO), 122.3 (C-1), 106.6 (C-2), 72.1 (d, J = 153.5, C(CH3)2), 63.4 (d, J = 6.6 Hz, OCH2CH3), 56.3 
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(OCH3), 23.2 (C(CH3)2), 16.4 (d, J = 5.5 Hz, OCH2CH3); 
31
P NMR (121 MHz, CDCl3) δ 23.40. HRMS-
ESI: calcd for C16H27NO7P
+
 [M+H]
+
 376.1520, found 376.1518. 
2-(Diethoxyphosphoryl)-N-(2-nitrobenzylidene)propan-2-amine oxide (2-NO2-PPN; 4j). The title 
compound was obtained from 3 (400 mg, 1.9 mmol) and 2-nitrobenzaldehyde (0.29 g, 1.9 mmol) in 
DCE (20 mL) as a yellow oil (0.29 g, 46%): 
1
H NMR (300 MHz, CDCl3) δ 9.01 (d, J = 8.1 Hz, 1H, H-
3), 8.32 (d, J = 2.0 Hz,1H, HC=NO), 8.03 (d, J = 8.3 Hz, 1H, H-6), 7.68 (t, J = 7.7 Hz, 1H, H-4), 7.52 (t, 
J = 7.5 Hz, 1H, H-5), 4.24 (m, 4H, 2 × OCH2CH3), 1.88 (s, 3H, C(CH3)2), 1.83 (s, 3H, C(CH3)2), 1.36 (t, 
J = 7.2 Hz, 6H, 2 × OCH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 147.5 (C-2), 133.3 (C-5), 130.1 (C-4), 
129.7 (C-6), 127.3 (d, J = 4.9 Hz, HC=NO), 124.8 (C-3), 124.6 (d, J = 1.6 Hz, C-1), 74.2 (d, J = 154.6 
Hz, C(CH3)2), 63.5 (d, J = 6.6 Hz, OCH2CH3), 23.2 (C(CH3)2), 16.4 (d, J = 6.0 Hz, OCH2CH3); 
31
P 
NMR (121 MHz, CDCl3) δ 22.34.  HRMS-ESI: calcd for C14H22N2O6P
+
 [M+H]
+
 345.1210, found 
345.1209. 
2-(Diethoxyphosphoryl)-N-(3-nitrobenzylidene)propan-2-amine oxide (3-NO2-PPN; 4k). The title 
compound was obtained from 3 (500 mg, 2.4 mmol) and 3-nitrobenzaldehyde (0.36 g 2.4 mmol) in DCE 
(15 mL) as white crystals from Et2O/pentane, 50:50 (0.67 g, 87%) mp 80.2 °C: 
1
H NMR (300 MHz, 
CDCl3) δ 9.18 (br s, 1H, H-2), 8.58 (br d, J = 8.0 Hz, 1H, H-2), 8.23 (br d, J = 8.0 Hz, 1H, H-6), 7.91 (d, 
J = 2.6 Hz, 1H, HC=NO), 7.58 (t, J = 8.0 Hz, 1H, H-5), 4.21 (m, 4H, 2 × OCH2CH3), 1.88 (s, 3H, 
C(CH3)2), 1.83 (s, 3H, C(CH3)2), 1.34 (t, J = 7.3 Hz, 6H, 2 × OCH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 
148.3 (C-3), 134.1 (C-6), 132.1 (C-1), 131.2 (d, J = 6.0 Hz, HC=NO), 129.4 (C-6), 124.5 (C-2), 123.3 
(C-4), 73.6 (d, J = 154.1 Hz, C(CH3)2), 63.6 (d, J = 7.2 Hz, OCH2CH3), 23.2 (C(CH3)2), 16.4 (d, J = 5.5 
Hz, OCH2CH3); 
31
P NMR (121 MHz, CDCl3) δ 22.52. HRMS-ESI: calcd for C14H22N2O6P
+
 [M+H]
+
 
345.1210, found 345.1212.  
2-(Diethoxyphosphoryl)-N-(4-nitrobenzylidene)propan-2-amine oxide (4-NO2-PPN; 4l). The title 
compound was obtained from 3 (600 mg, 2.85 mmol) and 4-nitrobenzaldehyde (0.43 g 2.85 mmol) in 
DCE (20 mL) as a white solid from Et2O/DCM, 70:30 (0.44 g, 46%), mp 139.9 °C (litt.
30
 139.9 °C): 
1
H 
NMR (300 MHz, CDCl3) δ 8.44 (d, J = 9.1 Hz, 2H, H-3), 8.26 (d, J = 9.1 Hz, 2H, H-2), 7.92 (d, J = 2.7 
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Hz 1H, HC=NO), 4.21 (m, 4H, 2 × OCH2CH3), 1.89 (s, 3H, C(CH3)2), 1.84 (s, 3H, C(CH3)2), 1.34 (t, J 
= 7.0 Hz, 6H, 2 × OCH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 147.8 (C-4), 136.2 (d, J = 1.5 Hz, C-1), 
131.5 (d, J = 4.4 Hz, HC=NO), 129.2 (C-2), 123.7 (C-3), 74.0 (d, J = 153.5 Hz, C(CH3)2), 63.6 (d, J = 
7.2 Hz, OCH2CH3), 23.2 (C(CH3)2), 16.4 (d, J = 5.5 Hz, OCH2CH3); 
31
P NMR (121 MHz, CDCl3) δ 
22.38. HRMS-ESI: calcd for C14H22N2O6P
+
 [M+H]
+
 345.1210, found 345.1210. 
2-(Diethoxyphosphoryl)-N-(4-acetamidobenzylidene)propan-2-amine oxide (4-NHAc-PPN; 4m). The 
title compound was obtained from 3 (600 mg, 2.85 mmol) and 4-acetamidobenzaldehyde (0.39 g 2.85 
mmol) in DCE (15 mL) as a white powder from Et2O (0.60 g, 73%), mp 154.7 °C: 
1
H NMR (300 MHz, 
DMSO-d6) δ 10.15 (s, 1H, NH), 8.28 (d, J = 8.8 Hz, 2H, H-3), 7.80 (d, J = 2.4 Hz, 1H, HC=NO), 7.63 
(d, J = 8.8 Hz, 2H, H-2), 4.07 (m, 4H, 2 × OCH2CH3), 2.05 (s, 3H, CH3), 1.72 (s, 3H, C(CH3)2), 1.67 (s, 
3H, C(CH3)2), 1.22 (t, J = 7.0 Hz, 6H, 2 × OCH2CH3); 
13
C NMR (75 MHz, DMSO-d6) δ 169.1 (CO), 
141.2 (C-4), 131.7 (d, J = 6.0 Hz, HC=NO), 130.0 (C-2), 126.3 (C-1), 118.6 (C-3), 72.4 (d, J = 155.7 
Hz, C(CH3)2), 63.9 (d, J = 6.6 Hz, OCH2CH3), 24.6 (CH3), 23.4 (C(CH3)2), 16.8 (d, J = 5.5 Hz, 
OCH2CH3); 
31
P NMR (121 MHz, DMSO-d6) δ 23.39. HRMS-ESI: calcd for C16H26N2O5P
+
 [M+H]
+
 
357.1574, found 357.1572. 
2-(Diethoxyphosphoryl)-N-(4-carboxybenzylidene)propan-2-amine oxide (4-CO2H-PPN; 4n). The 
title compound was obtained from 3 (400 mg, 2.0 mmol) and 4-carboxybenzaldehyde (0.29 g 2.0 mmol) 
in DCE (12.5 mL) as a white powder from Et2O (0.43 g, 66%), mp 141.9 °C: 
1
H NMR (400 MHz, 
CDCl3) δ 8.16 (d, J = 8.3 Hz, 2H, H-3), 7.75 (d, J = 8.3 Hz, 2H, H-2), 7.68 (d, J = 2.4 Hz, 1H, HC=NO), 
4.30 (m, 4H, 2 × OCH2CH3), 1.91 (s, 3H, C(CH3)2), 1.86 (s, 3H, C(CH3)2),1.39 (t, J = 7.0 Hz, 6H, 2 × 
OCH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 167.9 (CO), 133.9 (d, J = 1.1 Hz,C-1), 132.5 (d, J = 6.0 Hz, 
HC=NO), 131.5 (C-4), 129.9 (C-2), 128.5 (C-3), 74.0 (d, J = 157.9 Hz, C(CH3)2), 63.8 (d, J = 7.1 Hz, 
OCH2CH3), 23.3 (C(CH3)2), 16.4 (d, J = 6.0 Hz, OCH2CH3); 
31
P NMR (162 MHz, CDCl3) δ 23.61. 
HRMS-ESI: calcd for C15H23NO6P
+
 [M+H]
+
 344.1258, found 344.1260. 
2-(Diethoxyphosphoryl)-N-(4-ethoxycarbonylbenzylidene)propan-2-amine oxide (4-CO2Et-PPN; 4o). 
The title compound was obtained from 3 (300 mg, 1.4 mmol) and ethyl-4-formylbenzoate (253 mg, 1.4 
 31 
mmol) in DCE (12.5 mL) as a yellow oil (0.40 g, 76%): 
1
H NMR (300 MHz, CDCl3) δ 8.35 (d, J = 7.3 
Hz, 2H, H-3), 8.07 (d, J = 7.3 Hz, 2H, H-2), 7.80 (d, J = 2.2 Hz, 1H, HC=NO), 4.35 (q, J = 7.3 Hz, 2H, 
CO2CH2CH3), 4.20 (m, 4H, P(OCH2CH3)2), 1.87 (s, 3H, C(CH3)2), 1.82 (s, 3H, C(CH3)2), 1.37 (t, J = 
7.3 Hz, 3H, CO2CH2CH3), 1.31 (t, J = 7.0 Hz, 6H, P(OCH2CH3)2); 
13
C NMR (75 MHz, CDCl3) δ 165.9 
(CO), 133.4 (d, J = 2.3 Hz,C-1), 132.5 (d, J = 6.0 Hz, HC=NO), 131.5 (C-4), 129.6 (C-2), 128.6 (C-3), 
73.4 (d, J = 153.0 Hz, C(CH3)2), 63.5 (d, J = 7.5 Hz, P(OCH2CH3)2), 61.1 (CO2CH2CH3), 23.2 
(C(CH3)2), 16.5 (d, J = 6.0 Hz, P(OCH2CH3)2), 14.3 (CO2CH2CH3); 
31
P NMR (121 MHz, CDCl3) δ 
22.74. HRMS-ESI: calcd for C17H26NO6P
+
 [M+H]
+
 372.1571, found 372.1568. 
2-(Diethoxyphosphoryl)-N-(2-trifluoromethylbenzylidene)propan-2-amine oxide (2-CF3-PPN; 4p). 
The title compound was obtained from 3 (300 mg, 1.4 mmol) and 2-trifluoromethylbenzaldehyde (250 
mg, 1.4 mmol) in CH2Cl2 (15 mL) as a green oil (0.33 g, 60%): 
1
H NMR (300 MHz, CDCl3) δ 9.42 (d, J 
= 8.1 Hz, 1H, H-3), 7.80 (d, J = 2.5 Hz, 1H, HC=NO), 7.72 (d, J = 7.8 Hz, 1H, H-6), 7.62 (t, J = 7.7 Hz, 
1H, H-4), 7.47 (t, J = 7.7 Hz, 1H, H-5), 4.20 (m, 4 H, 2 × OCH2CH3), 1.88 (s, 3H, C(CH3)2), 1.83 (s, 
3H, C(CH3)2), 1.34 (t, J = 7.1 Hz, 6H, 2 × OCH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 132.0 (C-5), 129.4 
(C-4), 129.0 (C-6), 127.9 (br s, C-1 and HC=NO), 127.4 (q, J = 29.7, C-2), 125.7 (q, J = 6.1 Hz, C-3), 
124.0 (CF3), 74.0 (d, J = 154.1 Hz, C(CH3)2), 63.4 (d, J = 7.1 Hz, OCH2CH3), 23.1 (C(CH3)2), 16.2 (d, J 
= 5.5 Hz, OCH2CH3); 
31
P NMR (121 MHz, CDCl3) δ 22.36. HRMS-ESI: calcd for C15H22NO4PF3
+
 
[M+H]
+
 368.1233, found 368.1233. 
2-(Diethoxyphosphoryl)-N-(2,6-dimethylbenzylidene)propan-2-amine oxide (2,6-Me-PPN; 4q). The 
title compound was obtained from 3 (300 mg, 1.4 mmol) and 2,6-dimethylbenzaldehyde (190 mg, 1.4 
mmol) in THF (20 mL) as a white precipitate from Et2O (0.15 g, 32%), mp 66.7 °C:
 1
H NMR (300 
MHz, CDCl3) δ 7.89 (d, J = 1.8 Hz, 1H, HC=NO), 7.18 (t, J = 7.6 Hz, 1H, H-4), 7.05 (d, J = 7.6 Hz, 2H, 
H-3); 4.24 (m, 4H, P(OCH2CH3)2), 2.30 (s, 6H, 2 × CH3), 1.89 (s, 3H, C(CH3)2), 1.84 (s, 3H, C(CH3)2), 
1.36 (t, J = 7.1 Hz, 6H, P(OCH2CH3)2); 
13
C NMR (75 MHz, CDCl3) δ 137.6 (d, J = 1.5 Hz, C-2), 133.4 
(d, J = 5.5 Hz, HC=NO), 129.1 (C-4), 128.8 (C-1), 127.5 (C-3), 72.5 (d, J = 155.7 Hz, C(CH3)2), 63.35 
(d, J = 6.6 Hz, P(OCH2CH3)2), 23.6 (C(CH3)2), 19.8 (CH3), 16.5 (d, J = 6.1 Hz, P(OCH2CH3)2); 
31
P 
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NMR (121.5 MHz, CDCl3) δ 23.03. HRMS-ESI: calcd for C16H27NO4P
+
 [M+H]
+
 328.1672, found 
328.1672.  
2-(Diethoxyphosphoryl)-N-(4-chlorobenzylidene)propan-2-amine oxide (4-Cl-PPN; 4r). The title 
compound was obtained from 3 (300 mg, 1.4 mmol) and 4-chlorobenzaldehyde (199 mg, 1.4 mmol) in 
DCE (15 mL) as a white precipitate from pentane/Et2O, 7:3 (0.35 g, 74%), mp 79.2 °C (litt. [48] 81 °C): 
1
H NMR (300 MHz, CDCl3) δ 8.23 (d, J = 8.6 Hz, 2H, H-2), 7.74 (d, J = 2.8 Hz, 1H, HC=NO), 7.37 (d, 
J = 8.6 Hz, 2H, H-3), 4.20 (m, 4H, 2 × OCH2CH3), 1.86 (s, 3H, C(CH3)2), 1.81 (s, 3H, C(CH3)2), 1.33 (t, 
J = 7.2 Hz, 6H, 2 × OCH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 135.8 (C-4), 132.3 (d, J = 1.5 Hz, C-1), 
130.2 (C-2), 129.2 (d, J = 4.4 Hz, HC=NO), 128.7 (C-3), 73.0 (d, J = 154.1 Hz, C(CH3)2), 63.5 (d, J = 
6.6 Hz, OCH2CH3), 23.3 (C(CH3)2), 16.4 (d, J = 5.5 Hz, OCH2CH3); 
31
P NMR (121 MHz, CDCl3) δ 
22.92. HRMS-ESI: calcd for C14H22NO4PCl
+
 [M+H]
+
 334.0970, found 334.0971. 
 
X-ray Diffraction Analysis. X-ray crystal structures were collected at 293 K on a Bruker-Nonius 
Kappa CCD diffractometer using graphite-monochromated Mo Kα radiation (λ = 0.71073 Å). 
Crystal data for 4b: M = 315.29, space group C c, Hall group C -2yc, a = 11.5234(5) Å, b = 23.042(1) 
Å, c = 7.7077(4) Å,  = 90°, = 127.607(2)°,  = 90°. 
Crystal data for [4f+4f’] dimer: M = 331.30, space group P 21/c, Hall group -P 2ybc, a = 12.2694(14) 
Å, b = 34.361(3) Å, c = 11.7456(12) Å,  = 90°, = 95.870(12)°,  = 90°. 
Crystal data for 4k: M = 344.30, space group C c, Hall group C -2yc, a = 14.3666(4) Å, b = 
17.1483(4) Å, c = 7.19842(16) Å,  = 90°, = 94.052(2)°,  = 90°. 
Crystal data for 4q: M = 327.35, space group C c, Hall group C -2yc, a = 16.2402(9) Å, b = 
20.1187(2) Å, c = 9.1254(5) Å,  = 90°, = 143.236(12)°,  = 90°. 
CCDC reference numbers 1423593 (4b), 1423601 (4f), 1423594 (4k) and 1423602 (4q) contain the 
supplementary crystallographic data for the X-ray studies reported in this study. This material can be 
obtained free of charge at www.ccdc.cam.uk/conts/retrieving.html or from the Cambridge 
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Crystallographic Data Centre at deposit@ccdc.cam.ac.uk. This material is available free of charge via 
the Internet at http://pub.acs.org. 
 
EPR Experiments. Chemicals and UV irradiations. All chemicals, enzymes and solvents were 
analytical grade from Sigma-Aldrich, including diethylenetriaminepentaacetic acid (DTPA), H2O2, 
NaNO2, SNP and the spin trap PBN. Diethyl(1-(tert-butylamino)-eth-1-yl)phosphonate (7; see Figure 5 
inset) [69] and MGD [70] were synthesized according to reported procedures. 2-Nitroso propyl-2-
diethylphosphonate 6 was obtained by oxidation of aminophosphonate 1 by a modification of a reported 
procedure [71] (see Supporting Information). 
Doubly distilled deionized water was used in all experiments and all buffer solutions were filtered 
through a 0.2-µm Millipore filter prior to use. UV irradiations were carried out at 254 nm in a darkroom 
viewing cabinet using a 6-Watts VL-6.LC lamp (Fisher Biotec). 
Formation of PPNs spin adducts and their EPR detection. In all spin trapping experiments, the initial 
PPNs concentration was set at 30−50 mM, giving saturated aqueous solutions for the least soluble 
nitrones. For spin-trapping HO., a Fenton reagent was carried out, consisting of (final concentrations) 
FeSO4 (1 mM), H2O2 (3 mM) and the tested nitrone in 20 mM phosphate buffer with the pH adjusted to 
4.1−4.5. Alternatively, attempts to generate PPNs-OH were performed using either photolysis of 3% 
H2O2 or nucleophilic addition of water in the presence of FeCl3 (1 mM). The PPNs adducts of .CH3, 
.CH2OH, CH3.CHOH, CO2.
-
 and N3. were obtained in 20 mM phosphate buffer (pH 7.4) by running the 
Fenton reagent described above in the presence of the tested PPNs and the competitor (0.05−0.2 M) 
DMSO, methanol, ethanol, sodium formate and sodium azide, respectively. PPNs-SO3H adducts were 
prepared by incubating the nitrone with a mixture of sodium sulfite (20 mM) and 4 mM of either 
potassium dichromate or potassium ferricyanide in DTPA (1 mM)-supplemented phosphate buffer (20 
mM). PPNs-H adducts were prepared in water by aerial oxidation of the nitrone with ~ 5 mg of NaBH4. 
The methoxy radical adducts PPNs-OCH3 were obtained by adding ~1 mg of Pb(OAc)4 to the solution 
of the parent nitrone (0.05 M) in DMSO containing 25% methanol. PPNs-OOH adducts were obtained 
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by nucleophilic addition of 3% H2O2 in oxygenated pyridine and alternative attempts to obtain these 
nitroxides were performed using either the hypoxanthine (0.4 mM)/xanthine oxidase (0.02−0.03 
units/mL) O2.
-
 generator in DTPA (1 mM)-supplemented phosphate buffer (pH 7.0) or UV-photolysis of 
30% H2O2 in water. 
Samples were quickly introduced into calibrated 50−µL glass capillaries and 4096-points EPR spectra 
were recorded at room temperature within 40 s following initiation of free radical formation using a 
Bruker ESP 300 spectrometer (Karlsruhe, Germany) operating at X-band (9.79 GHz) with a 100 kHz 
modulation frequency, a microwave power of 10 mW and other settings specified in the appropriate 
figure legends. The magnetic field strength and microwave frequency were measured with a Bruker ER 
035M NMR gaussmeter and a Hewlett–Packard 5350B frequency counter, respectively. 
NO Spin trapping. The following stock solutions were prepared daily in deionized water: MGD (0.4 
M), FeSO4 (80 mM), and ascorbic acid (0.2 M). NO release was quantified in aqueous solutions of test 
compound submitted to UV photolysis using EPR detection of the [Fe(II)-MGD2−NO] complex [37]. 
Briefly, in a glass tube containing 0.4 mL of 20 mM test compound (i.e., PPNs, PBN or compounds 5 
and 6) were added in the following order: 50 µL ascH, 25 µL MGD and 25 µL FeSO4 as to reach the 
final concentrations of 20 mM, 20 mM and 4 mM for ascH, MGD and FeSO4, respectively. The pH of 
the solution was measured, the mixture was placed into a standard 10 mm quartz flat cell and submitted 
to UV photolysis for 70 min following addition of Fe(II). Unless indicated otherwise, EPR spectra of the 
[Fe
2+
-MGD2-NO] complex were acquired by signal-averaging 10 scans using the following parameters: 
microwave power, 10 mW; modulation frequency, 100 kHz; modulation amplitude, 0.198 mT; time 
constant, 163.84 ms; receiver gain, 1 × 10
5
; scan rate, 0.48 mT/s for a sweep width of 20 mT. Following 
EPR acquisition, the final pH of the solution was taken. In this assay, the known NO donors NaNO2 (20 
mM) and SNP (0.1 mM) were used as references. NO release was estimated from experiments in 
triplicate by double integration of computer-simulated [Fe
2+
-MGD2-NO] EPR signals, with 
concentrations expressed in arbitrary units (au). 
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Spin trapping in aortic rings and stability of frozen PPNs-CH3 spin adduct solutions. Frozen samples 
collected in the aortic rings preparations (see below) were sequentially thawed (< 1 min), placed into a 
glass capillaries and their spin adduct content was measured by EPR 45 s after thawing of the sample 
using the instrument settings as indicated above, except: modulation amplitude, 0.07 mT; time constant 
81.92 ms; receiver gain, 8 × 10
4
; scan rate, 0.31 mT/s for a sweep width of 13 mT; number of 
accumulated scans, 10. 
To check whether frozen storage of selected PPNs-CH3 adducts may alter their EPR signal intensity, 
they were produced from 35 mM PPN or nitrones 4b,d,e,g−i (sample volume, 1 mL) in phosphate buffer 
solution (pH 7.4) using the Fenton/DMSO generator described above. Prior to immediate storage in 
liquid nitrogen, a ~0.35 mL aliquot was placed in a capillary tube and a control EPR spectrum was 
recorded 5 min following Fe
2+
 addition. Four days following freezing, the samples were successively 
thawed and EPR-scanned 1 min following complete thawing of the sample. Instrument settings were as 
indicated above, except: modulation amplitude, 0.063 mT; time constant 20.48 ms; receiver gain, 2 × 
10
5
; scan rate, 0.15 mT/s for a sweep width of 13 mT; number of accumulated scans, 2. 
Throughout, determination of hfscs of spin adducts and quantitative estimations were performed using 
spectral simulations obtained by the program of Rockenbauer and Korecz [72]. 
 
Animal Procedures. Ethics. All animal care and experimental procedures were performed according 
to the guidelines of the Directive 2010/63/EU of the European Parliament. The protocol was approved 
by the National Research Committee for the projects ANR CES 2008-INTOX (2008−2012) and 
FEDER-AdiabaOx (2008, n°13851). The CNRS and Aix Marseille University have currently valid 
licences for animal housing and experimentation (agreement C13-055-06) delivered by the French 
Government and the study was under the supervision of a DVM at CNRS (agreement N°13-122). The 
following authors M. Ca., E. R. and S. P. are graduated for the Certificate in Small Animal Surgery and 
Experimentation (Aix-Marseille Université, Faculté de Pharmacie and Centre de Formation Permanente 
du CNRS DR12, Marseille). 
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Animals. Twelve male Sprague-Dawley rats weighing 200−250 g (CERJ, Le Genest St Isle, France) 
were used for the experiments. Animals were maintained in the local animal house under conventional 
conditions including an enrichment of the structural and social environment while promoting physical 
and cognitive activity, in a room with controlled temperature (22 ± 3 °C) and a reverse 12 h light/dark 
cycle with food (standard Teklad 2016 diet, Harlan Laboratories, Gannat, France) and water available ad 
libitum. 
Isolated aortic rings preparation and treatments. Rats were deeply anesthetized by intraperitoneal 
injection of sodium pentobarbital (100 mg/kg; Ceva Santé Animale, Libourne, France) before 
thoracotomy. The aortas were excised, cleaned, dissected into 3-mm ring segments, mounted between 
two stainless steel hooks and suspended at 37 °C in oxygenated, isolated 10 mL baths filled with a 
modified Krebs-Henseleit (KH) buffer (pH 7.35) containing (in mM): NaCl, 118; KCl, 4.7; KH2PO4, 
1.5; CaCl2, 2.5; MgSO4, 1.2; NaHCO3, 25; EDTA, 0.5; glucose, 11. The medium was renewed every 20 
min and continuously aerated with a 5% CO2−95% O2 gas mixture. Changes in tension were recorded 
using a standard apparatus (Harvard Apparatus, Les Ulis, France). Rings were first equilibrated for 60 
min at 1 g of resting tension and then stretched step by step until optimal and reproducible reference 
contraction to high-potassium physiological salt solution (KPSS, 123 mM KCl) was obtained. After a 
20-min washout, rings were contracted to 50% of the KPSS response by 10
-7 
M L-phenylephrine 
hydrochloride (Sigma-Aldrich) and endothelial integrity was tested by adding 10
-5 
M ACh perchlorate 
(Sigma-Aldrich) to the medium. The endothelium was considered intact if ACh induced a relaxation of 
80% or higher and the rings fulfilling this condition were reequilibrated for 30 min in KH buffer before 
the experiments. 
In a first set of experiments, we evaluated the effect of PPNs (200 µM) vs vehicle [KH + 0.1% 
DMSO] on the sensitivity of rings to SNP-induced relaxation. The cumulative concentration-response 
curve to SNP (10
-10−10-4 M) was determined in stretched rings placed in individual wells and 
preconstricted to 67−70% of the reference response by PE (5 × 10-6 M). Relaxation responses to SNP 
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were expressed as percentage of PE induced precontraction. Data are means of 3−6 independent 
experiments. 
In a second set of experiments, we used a reported procedure [58] to investigate whether pretreating 
rings by PPNs could protect against oxidative stress-induced impairment of ACh-induced 
vasorelaxation. Rings in wells containing 0.3 mL of [KH buffer + 0.1% DMSO] were incubated for 20 
min at 37 °C in the presence of a mixture of xanthine oxidase (10 mU/mL, 4 µL) and selected nitrones 
(200 µM). Generation of O2.- was then triggerred by adding aqueous xanthine (0.1 mM, 10 µL) to the 
incubation medium. After 10 min exposure to ROS, rings were preconstricted to 60% of the reference 
response with PE (~10
-6 
M) and dose-response curves for the vasorelaxing activity to cumulative ACh 
concentrations (10
-9−10-4 M) were established and compared to that obtained in normal incubation 
conditions. Relaxation responses to ACh were expressed as percentage of PE induced precontraction. 
Data are means of 6 independent experiments/group. 
In a third set of experiments, we examined the protection afforded by PPNs against tissue damage 
caused by endogenous O2.
-
 release as a result of NADPH stimulation of endothelial NADPH oxidase. 
Rings were first preincubated for 30 min in [KH buffer + 0.1% DMSO] containing the selected PPNs 
(200 µM) and 30 µM DTC (Sigma-Aldrich), then NADPH (1 mM) was added and incubation was 
prolonged up to 60 min. Two equal sets of individual rings were then transferred into separate wells 
prefilled with 0.3 mL of the same KH buffer/PPNs or vehicle/NADPH mixture as described above, and 
further incubated for 30 min in the dark at 37 °C. One subset of rings was kept for tissue protein 
carbonyls measurements and the other subset was used for EPR experiments (see below). Data were 
compared to control wells in which NADPH was omitted. In additional experiments, NADPH oxidase 
was inhibited by adding DPI (15 µM; Sigma-Aldrich) to the medium during the 30 min preincubation 
phase. 
Assay of proteins carbonyls. Protein carbonyls content was determined in ring tissues homogenates 
using the probe 7-hydrazino-4-nitrobenzo-2,1,3-oxadiazole (NBDH, Sigma-Aldrich) which forms highly 
fluorescent derivatives with several aldehydes via hydrazone formation [62]. Homogenates were 
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prepared by quickly homogenizing 0.1 g of fresh aortic tissue powdered in liquid N2 in nine bulks of a 
1.15% KCl ice-cold solution. After centrifugation (3000×g for 40 min at 2–3 °C), the supernatants were 
diluted 10-fold with PBS 0.1 X. Protein concentrations were determined using the BCA assay kit 
(Thermo Fisher Scientific). Protein carbonyls were derivatized with NBDH in 96-well microplates and 
were measured in the homogenates by fluorimetry (TECAN Infinite 200), with excitation at 500 nm and 
emission recorded at 560 nm. Protein carbonyls content are expressed in nanomoles/mg protein and are 
the means of 6−12 experiments/group made in triplicate and oxidized BSA was used for calibration. 
Preparation of samples for EPR analysis. To each well containing NADPH-stimulated rings in KH 
buffer for EPR experiments was added an aliquot of the selected PPNs in DMSO as to reach a final 
concentration of 15 mM nitrone and 1% DMSO, and the mixture was incubated for 20 additional min. 
For each tested PPNs, three 300 μL-aliquots of the mixture were placed in cryotubes and immediately 
stored in liquid nitrogen for delayed EPR analysis (see above).  
 
Data calculations and Statistics. Most results were obtained by constructing sigmoidal log 
concentration-response curves (Prism 5.0 software, GraphPad, San Diego, CA). Data are expressed as 
mean ± SD or SEM for the indicated number of independent experiments. Differences were analyzed 
using a one-way analysis of variance (ANOVA) followed by a posteriori Newman–Keuls test. 
Intergroup differences were considered to be significant at P < 0.05. 
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FIGURE CAPTIONS 
Figure 1. Structures of (A) PBN and its antioxidant-based derivatives BHT−PBN [21] and Trolox−PBN 
[22] successfully tested in in vitro and animal models of oxidative stress, and (B) phenolic (4a−4i) and 
non phenolic (4j−4q) derivatives of PPN (R = H). All PPNs are newly described except for compounds 
4c  [32], 4l [30] and 4r [29], and the following nitrones bear aromatic rings inspired from the phenolic 
acids: caffeic acid (4d), gallic acid (4g), ferulic acid (4h) and sinapic acid (4i). 
 
Figure 2. ORTEP view, drawn with 50% probability ellipsoids, showing atom numbering of (A) 3-OH-
PPN (4b) and (B) 2,6-Me-PPN (4q). The N(8)-O(9) bond of nitrone function is oriented towards the 
rear. Dashed lines indicate intramolecular H-bonds. Free radical addition occurs at C(1) (encircled). 
 
Figure 3. X-band (9.79 GHz) EPR spectra at room temperature and associated computer simulations of 
(A) 2-CF3-PPN-SO3H; (B) 4-OH-3,5-OMe-PPN-SO3H; (C) 4-CO2H-PPN-OOH and (D) 4-OH-3-OMe-
PPN-OCH3. Spectra were obtained in phosphate buffer (pH 7.4; traces A−C) or DMSO/methanol 
(75:25; trace D) at 10 mW microwave power and 100 kHz modulation frequency using the parameters 
(for spectra A−D): modulation amplitude 0.011, 0.035, 0.063, 0.035 mT; time constant, 40.96, 40.96, 
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40.96, 81.92 ms; receiver gain, 4, 8, 6.3, 3.2 × 10
5
; sweep rate, 0.24, 0.21, 0.12, 0.15 mT/s; number of 
accumulated scans, 5, 5, 4, 2. 
 
Figure 4. [Fe(II)−MGD2−NO] formation from aqueous PPNs UV-photolyzed for 70 min in the presence 
of ascorbic acid (20 mM), MGD (20 mM) and FeSO4 (4 mM). (A) Room temperature EPR spectrum 
recorded from saturated aqueous 4-Cl-PPN 4r and simulation consistent with a mixture of 44% nitrosyl-
iron complex (low-field triplet) and decomposition signals consisting of an alkyl radical adduct (as a 12-
lines spectrum) and a triplet (●) which account for 35% and 21% of the total signal, respectively. EPR 
settings: microwave power, 20 mW, modulation amplitude, 0.056 mT; receiver gain, 4 × 10
4
; time 
constant, 40.96 ms; sweep time for each scan, 0.24 mT/s for a sweep width of 20 mT; number of 
accumulated scans, 2. (B) Mean ± SD formation of [Fe(II)−MGD2−NO] from nitrones (20 mM) and 
optimized C(1)−N(8) bond lengths of the corresponding hydroxylamine 5 calculated using HyperChem 
8.0 Pro. Black bars indicate compounds with ortho aryl substitution. One-way ANOVA (P < 0.01) 
followed by Newman-Keuls test: *P < 0.01 vs PPN (n = 3). 
 
Figure 5. Mechanism of light-induced NO release by PPNs in aqueous medium. Inset: chemical 
structure of aminophosphonate 7 which does not release NO in aqueous solution. 
 
Figure 6. (A) Effect of PPNs (200 µM) on the responses to ACh following treatment with xanthine (0.1 
mM)/xanthine oxidase (10 mU/mL). Data are means ± SEM of 3−6 experiments/group. Two-way 
ANOVA followed by Newman-Keuls test: 
+
P < 0.05 vs xanthine/xanthine oxidase group. (B) Tissue 
protein carbonyls following exposure to NADPH (1 mM) for 60 min in the presence of PPNs. Data are 
means ± SEM of 9−12 experiments/group. One-way ANOVA (P < 0.01) followed by Newman-Keuls 
test: 
*
P < 0.05, 
**
P < 0.01 and 
***
P < 0.001 vs vehicle; 
§
P < 0.01 vs PPN group. 
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Figure 7. Indirect spin trapping evidence for hydroxyl radical formation in the supernatant of rat aortic 
rings stimulated by NADPH (1 mM) for 80 min. After 60 min NADPH stimulation in KH buffer, the 
spin trap (15 mM) diluted in DMSO (1% final concentration) was added to the medium and incubated 
with rings for 20 min. (A) EPR signal recorded in (a) the complete incubation system containing 
NADPH, DMSO, DTC (30 µM) and 3-OH-PPN 4b. Simulation was consistent with a mixture of 3-OH-
PPN-CH3 (94%; see hfscs in Table 2) and a decomposition signal (6%) with hfscs: aN = 1.399; aP = 
3.825 mT; (b) complete incubation system minus NADPH; (c) complete incubation system in the 
presence of DPI (15 µM). (B) Mean ± SD of methyl radical spin adduct EPR intensity. One-way 
ANOVA (P < 0.01) followed by Newman-Keuls test: *P < 0.01 vs PPN (n = 3). EPR settings: 
microwave power, 10 mW, modulation amplitude, 0.07 mT; receiver gain, 8 × 10
4
; time constant, 81.92 
ms; sweep time for each scan, 0.31 mT/s for a sweep width of 13 mT; number of accumulated scans, 10. 
 
Abbreviations used 
PBN, -phenyl-N-tert-butylnitrone; PBNs, PBN-type nitrones; PPN, 2-(Diethoxyphosphoryl)-N-
(benzylidene)propan-2-amine oxide; PPNs, aryl substituted PPN-type nitrones; ROS, reactive oxygen 
species; STW, spectrum total width; MGD, N-methyl-D-glucamide dithiocarbamate; DTPA, 
diethylenetriaminepentaacetic acid; SNP, sodium nitroprusside; KH, Krebs-Henseleit; KPSS, high-
potassium physiological salt solution; ACh, acetylcholine; PE, L-phenylephrine hydrochloride; DMEM, 
Dulbecco’s modified Eagle’s medium; DPI, diphenylene iodonium, DTC, diethyldithiocarbamate. 
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Table 1. Selected Crystallographic Data of PPNs
a
 
N
O
P
2
6
5
4
3
8
9
OEt
OEt
O
1
7
10
11
12
 
____________________________________________________________________________________ 
PPNs Bond lengths (Å) Dihedral angles (°) 
 ________________________ _________________________________________ 
 C(1)−C(2) C(1)−N(8) O(9)−N(8)−C(10)−P(11) N(8)−C(1)−C(2)−C(3) 
____________________________________________________________________________________ 
4b 1.446(5) 1.302(5) −91.4(0) 1.3(3) 
4f
b
 1.445(7) 1.297(6) −72.1(1) 17.5(7) 
4f’b 1.445(7) 1.297(6) −72.1(3) 17.2(5) 
4k 1.448(5) 1.312(5) 64.9(2) 3.3(1) 
4q 1.471(3) 1.293(2) −42.4(4) −111.4(6) 
4c
c
 1.448(3) 1.302(3) 67.3 0.4 
____________________________________________________________________________________ 
a
Values in parentheses are the estimated SD. 
b
Represent the geometries of the two structures packed in the 
crystal lattice (Supporting Information, Figure S1B−D). cData from Ref [32]. 
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Table 2. Hyperfine Splitting Constants (hfscs) of Different Radical Adducts of Various Hydroxy and Methoxy Substituted PPNs 
_____________________________________________________________________________________________________________________ 
Radical Solvent hfscs PPN 4-OH 3-OH 2-OH 2,4-OH 3,4-OH 3,5-OH 3,4,5-OH 4-OH-3-OMe 4-OH-3,5-OMe 
 (mT)  (4c) (4b) (4a) (4f) (4d) (4e) (4g) (4h) (4i) 
_____________________________________________________________________________________________________________________ 
•CH3 nPB
a
 aN 1.495
b,c
 1.508 1.490 1.505 1.518 1.502 1.483 1.500 1.502 1.494 
  aH 0.348 0.332 0.357 0.433 0.411 0.346 0.375 0.367 0.348 0.367 
  aP 4.673 4.659 4.669 4.774 4.731 4.662 4.674 4.672 4.647 4.625 
•CH2OH nPB aN 1.462
b
 1.469 1.457 1.464 1.474 1.469 1.458 1.466 1.466 1.461 
  aH 0.338 0.321 0.336 0.406 0.401 0.332 0.350 0.347 0.325 0.332 
  aP 4.212 4.219 4.185 4.193 4.188 4.202 4.188 4.196 4.210 4.188 
•CH(OH)CH3 nPB aN 1.473
b
 1.481 1.468 1.482 1.510 1.479 1.466 1.477 1.479 1.474 
  aH 0.320 0.310 0.327 0.350 0.364 0.322 0.333 0.342 0.322 0.331 
  aP 4.093 4.100 4.081 4.102 4.095 4.075 4.072 4.080 4.069 4.062 
•CO2
-
 nPB aN 1.451
b
 1.456 1.447 1.470 1.479
 d
 1.453 1.444 1.451 1.452 1.447 
  aH 0.461 0.466 0.444 0.463 0.481 0.454 0.427 0.447 0.458 0.445 
  aP 4.997 5.067 4.972 4.114 4.190 5.043 4.952 5.003 5.081 5.093 
•OOH pyridine aN 1.277
e
 1.295
 f
 1.282 ns
g
 ns 1.391 1.291 1.396 1.299 PPNsOX-1
h
 
  aH 0.124 0.138 0.140   0.290 0.172 0.296 0.154 
  aP 3.861 3.858 3.747   4.036 3.645 3.900 3.830 
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Table 2 (continued 1) 
 
•OCH3 DMSO aN 1.319
i
 1.338
f
 1.321 1.356 1.371 1.289 1.325 PPNsOX-2
h
 1.307 PPNsOX-3
h
 
  aH 0.248 0.280 0.273 0.344 0.367 0.185 0.297  0.285 
  aP 3.899 3.921 3.847 3.983 4.014 3.967
j
 3.852  4.017 
•SO3
-
 nPB aN 1.365 1.375 1.362 1.373 1.378 1.373 1.358 ns 1.372 1.366 
  aH 0.133 0.129 0.128 0.148 0.137 0.122 0.123  0.121 0.120 
  aP 4.354 4.442 4.366 4.255 4.311 4.440 4.394  4.462 4.479 
_____________________________________________________________________________________________________________________ 
a 
nPB = phosphate buffer, pH 7.4. 
b 
Data (mT) from Ref. [29] in phosphate buffer, pH 7.0: PPN-CH3: aN = 1.50; aH = 0.36; aP = 4.69; PPN-
CH2OH: aN = 1.47; aH = 0.34; aP = 4.23; PPN-CH(OH)CH3: aN = 1.48; aH = 0.31; aP = 4.12; PPN-CO2H: aN = 1.45; aH = 0.46; aP = 5.02. 
c
 g = 
2.00550 (this work). 
d
g = 2.00546 (this work). 
e
Data from Ref. [29]  in pyridine: aN = 1.26; aH = 0.12; aP = 3.85 mT. 
f 
Data (mT) from Ref. [32]: 4-
OH-PPN-OOH in pyridine: aN = 1.31; aH = 0.16; aP = 3.86, and 4-OH-PPN-OCH3 in DMSO: aN = 1.34; aH = 0.28; aP = 3.89.
 g
ns = no signal. 
hDecomposition signal assigned to the benzoyl nitroxide (PPNsOX), i.e., ArC(O)−N(O•)−C(Me2)−P(O)(OEt)2; hfscs (mT): PPNsOX-1: aN = 
0.500; aP = 0.932; aH = 0.371(2H), 0.177 (6H), 0.090; PPNsOX-2: aN = 0.245; aP = 0.772; aH = 0.241 (2H), 0.103 (1H), 0.040 (2H); PPNsOX-3: aN 
= 0.449; aP = 1.406; aH = 0.222 (2H), 0.117). 
i
Data from Ref. [34]  in water/methanol (80:20): aN = 1.38; aH = 0.33; aP = 3.99 mT. 
j
A satisfactory fit 
was obtained assuming a mixture of the expected methoxy radical adduct (36%) and the corresponding PPNsOX (62%) having the hfscs: aN = 
0.526; aP = 0.705; aH = 0.438 (2H), 0.355, 0.192, 0.082 mT. 
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Table 3. EPR Parameters of Different Radical Adducts of 4-Chloro, 2-Trifluoromethyl and Various Nitro and Carboxy Substituted PPNs 
____________________________________________________________________________________________________ 
Radical Solvent hfscs 4-Cl 4-NO2 3-NO2 2-NO2 4-AcNH 4-CO2H 4-CO2Et 2-CF3 
 (mT) (4r) (4l) (4k) (4j) (4m) (4n) (4o) (4p) 
____________________________________________________________________________________________________ 
•CH3 nPB
a
 aN 1.488
b
 1.465
c
 1.471 1.453 1.490 1.479 1.475 1.476 
  aH 0.314 0.294 0.267 0.469 0.317 0.329 0.326 0.580 
  aP 4.643 4.644 4.660 4.765 4.658 4.657 4.634
d
 5.016 
•CH2OH nPB aN 1.454
b
 1.434
c
 1.434 1.420 1.454 1.445 1.439 1.430 
  aH 0.293 0.278 0.247 0.379 0.312 0.303 0.293 0.501 
  aP 4.256 4.326 4.394 4.308 4.259 4.267 4.248 4.342 
•CH(OH)CH3 nPB aN 1.465
b
 1.439
c
 1.442 1.423 1.469 1.454 1.451 1.430 
  aH 0.308 0.268 0.247 0.327 0.303 0.296 0.280 0.367 
  aP 4.130 4.198 4.316 4.474 4.119 4.152 4.101 4.142 
•CO2
-
 nPB aN 1.448
b,e
 1.434
c
 1.435 1.426 1.451 1.441 1.441 1.472 
  aH 0.425 0.370 0.364 0.327 0.442 0.406 0.403 0.536 
  aP 5.013 4.947 5.052 3.876 5.021 4.949 4.952 3.842 
•OOH pyridine aN ns
f,g
 1.247
h
 1.251 1.251 1.291 1.261 ns ns 
  aH  0.112 0.106 0.174 0.141 0.117 
  aP  3.985 4.108 3.788 3.856 3.914 
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Table 3 (continued 1) 
•OOH water aN 1.357 1.333 1.366 1.333 1.312 1.346 1.348 1.356 
  aH 0.200 0.168 0.235 0.307 0.179 0.196 0.188 0.444 
  aP 4.230 4.212 4.173 4.015 4.232 4.195 4.201 4.411 
•OCH3 DMSO aN 1.308
i
 1.296 1.297 1.283 1.268 1.311 1.300 1.308 
  aH 0.231 0.195 0.195 0.335 0.135 0.229 0.234 0.527 
  aP 3.900 4.027 4.027 3.823 4.062 3.824 3.887 4.308
j
  
•SO3
-
 nPB aN 1.362 1.333 1.331 1.332 1.367 1.361 1.354 1.341 
  aH 0.121 0.168 0.226 0.197 0.125 0.123 0.114 0.175 
  aP 4.467 3.978 4.338 4.564 4.441 4.439 4.466 3.990 
•OH acPB
a
 aN 1.420
b,k
 1.402
c,l
 1.398
m
 1.426 ns 1.414
n
 1.409
o
 ns 
  aH 0.219 0.192 0.178 0.361  0.216 0.208 
  aP 4.339 4.288 4.369 3.936  4.308 4.300 
•N3 nPB aN 1.392 1.370 1.368 ns ns 1.388 1.381 ns 
  aH 0.173 0.183 0.162   0.200 0.188 
  aP 4.451 4.420 4.446   4.476 4.421 
  aNβ 0.187 0.192 0.201   0.182 0.180 
•H water aN ns 1.508
c
 1.506 1.545 ns 1.525 1.512 ns 
  aH  1.042(2H) 1.065(2H) 1.325(2H)  1.037(2H) 1.029(2H) 
  aP  4.798 4.819 4.879  4.846 4.816 
____________________________________________________________________________________________________ 
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Table 3 (continued 2) 
 
a Phosphate buffer, pH 7.4 (nPB) or pH 4.1−4.5 (acPB). b Data (mT) from Ref. [29] in phosphate buffer, pH 7.0: 4-Cl-PPN-CH3: aN = 1.50; aH = 
0.33; aP = 4.67; 4-Cl-PPN-CH2OH: aN = 1.47; aH = 0.31; aP = 4.34; 4-Cl-PPN-CH(OH)CH3: aN = 1.47; aH = 0.30; aP = 4.20; 4-Cl-PPN-CO2H: aN = 
1.46; aH = 0.42; aP = 5.02; 4-Cl-PPN-OH: aN = 1.45; aH = 0.23; aP = 4.36. 
c
Data (mT) from Ref. [30] in water: 4-NO2-PPN-CH3: aN = 1.455; aH = 
0.307; aP = 4.633; 4-NO2-PPN-CH2OH: aN = 1.435; aH = 0.287; aP = 4.305; 4-NO2-PPN-CH(OH)CH3: aN = 1.449; aH = 0.264; aP = 4.279; 4-NO2-
PPN-CO2H: aN = 1.414; aH = 0.350; aP = 4.919; 4-NO2-PPN-OH: aN = 1.440; aH = 0.228; aP = 4.742; 4-NO2-PPN-H: aN = 1.507; aH (2H) = 1.039; 
aP = 4.794. 
d
g = 2.00549 (this work). 
e
g = 2.00543 (this work). 
f
ns = no signal. 
g
Data (mT) from Ref. [30]: 4-Cl-PPN-OOH in pyridine: aN = 1.27; 
aH = 0.12; aP = 3.96. 
i
Data from Ref. [34]  in water/methanol (80:20): aN = 1.38; aH = 0.32; aP = 4.17 mT. g-values (this work): 
h
2.00598; 
j
2.00581; 
k
2.00564; 
l
2.00568; 
m
2.00566; 
n
2.00568; 
o
2.00565. 
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Table 4. In Vitro Antioxidant Properties
a
 and Predicted Lipophilicity of PPNs Compared to Reference 
Compounds 
________________________________________________________________________________ 
Compound DPPH TRAP superoxide quenching
b
 AlogP
c
 
 EC50 (µM) (TE)
d
 IC50 (µM) 
________________________________________________________________________________ 
PPN > 1000 ~ 0.02 375.0 ± 26.8 1.65 
2-OH-PPN  4a > 1000 0.25 ± 0.06 33.5 ± 2.6 1.30 
3-OH-PPN  4b > 1000 0.10 ± 0.02 123.0 ± 6.5 1.32 
4-OH-PPN  4c > 1000 0.65 ± 0.06 60.8 ± 1.9 1.33 
3,4-OH-PPN  4d 22 ± 1 2.22 ± 0.16 0.2  ± 0.1 1.26 
3,5-OH-PPN  4e > 1000 0.70 ± 0.04 187.0 ± 14.9 1.26 
2,4-OH-PPN  4f > 1000 1.61 ± 0.15 43.3 ± 3.9 1.25 
3,4,5-OH-PPN  4g 19 ± 1 1.46 ± 0.09 0.9 ± 0.1 0.94 
4-OH-3-OMe-PPN  4h 254 ± 9 1.91 ± 0.10 28.6 ± 1.1 1.39 
4-OH-3,5-OMe-PPN  4i 190 ± 11 1.44 ± 0.13 72.1 ± 3.9 1.40 
2-NO2-PPN  4j > 1000 ~ 0.02 30.0 ± 1.5 1.63 
3-NO2-PPN  4k > 1000 ~ 0.02 52.3 ± 2.9 1.63 
4-NO2-PPN  4l > 1000 ~ 0.02 9.3 ± 0.3 1.65 
4-AcNH-PPN  4m > 1000 ~ 0.02 26.3 ± 5.0 1.39 
4-CO2H-PPN  4n > 1000 ~ 0.02 4.1 ± 0.1 1.28 
4-CO2Et-PPN  4o > 1000 0.16 ± 0.02 6.8 ± 0.3 2.00 
2-CF3-PPN  4p > 1000 ~ 0.02 4.2 ± 0.2 2.34 
2,6-Me-PPN  4q > 1000 ~ 0.02 350.2 ± 12.8 1.98 
PBN > 1000 ~ 0.02 > 4000 1.40 
CO2H
HO
HO
OH  7 ± 1 1.18 ± 0.07 0.7 ± 0.2 1.17 
Gallic acid 
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Table 4 (continued) 
 
HO
OH
CO2H
 17 ± 1 2.73 ± 0.13 0.1 ± 0.0 1.25 
Caffeic acid 
HO
OMe
CO2H
 61 ± 4 2.16 ± 0.15 34.9 ± 0.7 1.58 
Ferulic acid 
HO
OMe
CO2HMeO
 35 ± 1 1.64 ± 0.10 22.4 ± 0.5 1.63 
Sinapic acid 
Trolox 20 ± 1 1.00 13.3 ± 1.1 2.73 
Quercetin 13 ± 2 6.28 ± 0.06 0.5 ± 0.1 1.81 
________________________________________________________________________________ 
aExperimental details are given in Supporting Information. Data are means ± SEM of 3−10 
independent experiments made in triplicate. 
b
Superoxide generator was the allopurinol-xanthine oxidase 
system and scavenging activity was determined by assaying lucigenin chemiluminescence. 
c
Obtained by 
using the ALOGPS 2.1 software (www.vcclab.org/lab/alogps/). 
d
TE, equivalent Trolox; TRAP ~ 0.02 
for inactive compounds. 
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Table 5. Effect of Selected PPNs and Related Compounds on Cytotoxicity Against A549 Cells
a
 and Potencies for Relaxation to SNP of 
Endothelium-Intact Rat Aortic Rings
b
 
___________________________________________________________________________________________________________ 
Compound Cytotoxicity assay Response to SNP 
 ________________________________________________ __________________________ 
 FMCA ATP MTT LDH sensitivity relaxation 
 ____________________________________ 
 IC50 (mM)
c
 ∆ (%)d pEC50
e
 Rmax (%)
f
 
___________________________________________________________________________________________________________ 
vehicle ____ ____ ____ ____ 7.98 ± 0.02 99 ± 3 
PPN 13.58 ± 0.12 12.14 ± 0.51 13.03 ± 0.42 15 ± 1* 8.54 ± 0.06* 100 ± 2 
PBN 8.30 ± 0.27 9.32 ± 0.29 10.20 ± 0.13 18 ± 2* 8.22 ± 0.12 98 ± 2 
2-OH-PPN  4a 8.23 ± 0.25 9.25 ± 0.19 8.98 ± 0.36 17 ± 2* 8.24 ± 0.08 99 ± 2 
3-OH-PPN  4b 7.56 ± 0.27 8.25 ± 0.21 7.48 ± 0.97 19 ± 2* 8.30 ± 0.10 99 ± 2 
4-OH-PPN  4c 10.47 ± 0.49 12.36 ± 0.31 13.02 ± 0.32 12 ± 4 8.25 ± 0.10 99 ± 2 
3,4-OH-PPN  4d 1.87 ± 0.08 1.92 ± 0.16 1.30 ± 0.27 28 ± 3** 9.01 ± 0.06** 103 ± 3 
3,5-OH-PPN  4e 4.95 ± 0.33 6.98 ± 0.25 7.91 ± 0.32 14 ± 2* 8.28 ± 0.11 98 ± 4 
3,4,5-OH-PPN  4g 0.56 ± 0.05 0.63 ± 0.08 0.73 ± 0.24 36 ± 3** 8.98 ± 0.11** 104 ± 3 
4-OH-3-OMe-PPN  4h 6.41 ± 0.58 4.32 ± 0.29 3.87 ± 0.18 19 ± 3* 8.99 ± 0.03** 100 ± 3 
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Table 5 (continued 1) 
 
4-OH-3,5-OMe-PPN  4i 12.01 ± 0.47 14.77 ± 0.58 15.33 ± 0.18 12 ± 4* 8.66 ± 0.04* 101 ± 2 
2-NO2-PPN  4j 2.20 ± 0.07 1.35 ± 0.35 1.33 ± 0.75 58 ± 5** 8.91 ± 0.06* 100 ± 2 
4-NO2-PPN  4l 1.12 ± 0.10 0.95 ± 0.07 1.26 ± 0.07 54 ± 6** 8.37 ± 0.05* 101 ± 1 
4-CO2H-PPN  4n 7.83 ± 1.04 8.23 ± 0.42 7.28 ± 0.75 15 ± 3* nd
g
 nd 
4-CO2Et-PPN  4o 4.53 ± 0.28 3.56 ± 0.41 3.51 ± 0.38 nd nd nd 
2-CF3-PPN  4p 2.15 ± 0.14 2.71 ± 0.18 4.23 ± 0.25 nd 8.99 ± 0.03** 104 ± 2 
2,6-Me-PPN  4q 4.74 ± 0.36 5.25 ± 0.23 4.41 ± 0.36 nd 9.03 ± 0.04** 105 ± 3 
Gallic acid 0.39 ± 0.02 0.39 ± 0.01 0.35 ± 0.02 nd nd nd 
Caffeic acid 0.49 ± 0.15 0.73 ± 0.12 0.67 ± 0.10 nd nd nd 
Ferulic acid 2.56 ± 0.21 3.23 ± 0.09 3.13 ± 0.08 nd nd nd 
Sinapic acid 4.56 ± 0.13 5.71 ± 0.12 4.88 ± 0.10 nd nd nd 
___________________________________________________________________________________________________________ 
a
Cells were seeded at 2.5 × 10
4
 cells/well in DMEM until confluence and were then treated with compounds either at 0.01−30 mM for 48 h or at 
15 mM for 3 h in [DMEM +0.5% DMSO] (vehicle). Data are means ± SD of 3−6 independent experiments bRings were precontracted with 5 × 10-6 
M phenylephrine (PE) and the response to SNP (10
-10−10-4 M) was measured in [KH + 0.1% DMSO] medium (vehicle) in the presence or absence 
of tested compounds (200 µM). 
c
IC50 defined as the concentration of compound resulting in 50% cell viability after 48 h and calculated from 
concentration-response curves. 
d
Percentage of decrease of intracellular LDH content in cells treated with compounds at 15 mM for 3 h vs vehicle. 
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Table 5 (continued 2) 
 
e
pEC50 defined as the −log concentration of SNP resulting in 50% inhibition of the maximum response to PE. 
f
Rmax defined as the calculated 
maximal relaxation response to SNP. 
g
nd = not determined. One way-ANOVA followed by Newman-Keuls test: *P < 0.05 and **P < 0.01 vs 
corresponding vehicle. 
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Table 6. Effect of Nitrones (200 µM) on the Potencies for Relaxation to ACh in Endothelium-Intact Rat 
Aortic Rings Exposed to Superoxide Radicals 
______________________________________________________ 
 Condition Response to ACh
a
 
 _________________________ 
  pEC50
b
 Rmax (%)
c
 
______________________________________________________ 
 vehicle 7.66 ± 0.06 95 ± 2 
 vehicle + O2.
-
 6.39 ± 0.08* 56 ± 2* 
 PBN + O2.
-
 6.76 ± 0.22 62 ± 4 
 PPN + O2.
-
 6.83 ± 0.08 75 ± 2 
 3,4-OH-PPN 4d + O2.
-
 7.39 ± 0.05
§
 93 ± 1
§
 
 3,4,5-OH-PPN 4g + O2.
-
 7.55 ± 0.05
§
 93 ± 1
§
 
 4-OH-3-OMe-PPN 4h + O2.
-
 7.27 ± 0.04
§
 86 ± 1
§
 
 4-OH-3,5-OMe-PPN 4i + O2.
-
 7.17 ± 0.08
§
 77 ± 2
§
 
______________________________________________________ 
a
Rings were exposed for 10 min to xanthine (0.1 mM)-xanthine oxidase (10 mU/mL) before 
precontraction with PE (~10
-6
 M). The response to ACh (10
-9−10-4 M) was then determined in [KH + 
0.1% DMSO] medium (vehicle) in the presence or absence of compounds. Data are means ± SD of 6 
independent experiments/group. 
b
pEC50 defined as the −log concentration of ACh resulting in 50% 
inhibition of the maximum response to PE. 
c
Rmax defined as the calculated maximal relaxation response 
to ACh. One-way ANOVA followed by Newman-Keuls test: *P < 0.05 vs vehicle; 
§
P < 0.05 vs vehicle 
+ O2.
-
. 
 
